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Anti-inflammatory Pharmacology of Histone Deacetylase Inhibitors 
in Pre-clinical Models of Rheumatoid Arthritis 
 
HDAC inhibitors have emerged as a novel class of anti-cancer agents. Their anti-
rheumatic activities had been documented in various pre-clinical RA models. However, their 
anti-rheumatic mechanisms of action are not well elucidated. The work that was carried out 
for this thesis aimed to elucidate the anti-inflammatory and anti-rheumatic mechanisms of 
action of HDAC inhibitors. Inhibition of RASF proliferation, suppression of pro-
inflammatory cytokines, chemokines and NO as well as down-regulation of angiogenesis, 
chemotaxis and MMPs may provide beneficial effects in RA. The aforementioned effects 
may be a result of CDK inhibitor p21 up-regulation as well as MAPK and NF-κB inhibition. 
Hence, HDAC inhibitors appear to be an innovative strategy for RA management. 
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1.1 Rheumatoid Arthritis (RA) 
RA is one of the most common forms of arthritis [1-3]. It is a chronic, 
systemic, inflammatory disorder that affects small diarthrodial joints of the hands and 
feet [1-3]. Pain, stiffness and symmetrical swelling of peripheral joints are hallmarks 
of the disease [2]. It may lead to irreversible joint destruction, substantial disability 
and even death when left unchecked [1-3].  
 
The etiology of RA remains elusive [4, 5]. However, it is generally believed to 
be initiated by antigen-dependent activation of CD4
+
 T cells which amplify immune 
responses by stimulating B cells, monocytes, macrophages, synovial fibroblasts, 
chondrocytes and osteoclasts [2, 4]. Pro-inflammatory cytokines like interleukin (IL)-
1, IL-6 and tumor necrosis factor (TNF)- are released. The cytokines are pivotal for 
disease development because they cause synovial inflammation [2, 4]. Histological 
analyses showed that the inflamed synovium is accompanied by pronounced 
angiogenesis, cellular hyperplasia,  inflammatory leucocyte influx and changes in the 
expression of cell-surface adhesion molecules, proteinases, proteinase inhibitors  as 
well as other cytokines [2, 4]. In turn, synovial hyperplasia leads to panus formation 
which is a characteristic manifestation in RA [2, 4]. The transformed synovial tissues 
possess high levels of degradative enzymes such as matrix metalloproteinases 
(MMPs), serine proteases and aggrecanases [1, 2]. Eventually, the panus invades the 
joint space to digest the extracellular matrix (ECM) and subsequently destroys 
articular structures [1, 2]. In addition to cartilage damage, bone destruction or 
resorption are accelerated due to osteoclastogenesis driven by CD4
+
 T cells that 
express osteoprotegerin ligands [2, 4]. The integrated immune response and 
pathogenesis of RA are illustrated in Figure 1.1. 







Figure 1.1 The integrated immune response and pathogenesis of RA – modified from 
Choy HS and Panayi GS [4].  
Th2, type 2 helper T cell; Th0, precursor of type 1 and type 2 helper T cells; OPGL, 
osteoprotegerin ligand 
 
RA remains incurable at present [3-4]. The goals in treatment involve 
decreasing pain and inflammation as well as preventing and controlling joint damage 
and loss of function. Current pharmacotherapy makes use of general analgesics, non-
steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and disease modifying 
anti-rheumatic drugs (DMARDs) which may be synthetic or biologic [3]. General 
analgesics and NSAIDs do not alter disease course nor prevent joint destruction [3]. 




Furthermore, NSAIDS can result in gastrointestinal side effects. The advent of 
cyclooxygenase (COX)-2 inhibitors provided some reprieve from gastrointestinal 
disturbances [3, 6] but cardiovascular adverse events prevail. Subsequently, COX-2 
inhibitors like rofecoxib and valdecoxib were withdrawn [3, 7, 8]. Glucocorticoids are 
potent anti-inflammatory agents [3] and direct joint injections are advocated by 
rheumatologists [3]. However, the same joint cannot be injected more than once every 
3 months [3]. Synthetic DMARDs are a heterogeneous class comprising of anti-
malarials, azathioprine, cyclophosphamide, gold, leflunomide, methotrexate (MTX), 
penicillamine and sulfasalazine [3]. MTX is the gold standard DMARD [3]. Clinical 
efficacy and adverse effects of synthetic DMARDs had been extensively reviewed [2, 
3, 5, 8]. Unfortunately, RA management with synthetic DMARDs is still not optimal 
[9]. Few patients achieve long-term remission with a single DMARD. Majority of 
them will eventually discontinue or switch DMARD because of adverse effects or 
tachyphylaxis [3, 9]. Combination with DMARDs had been advocated and most of 
them include MTX [10]. Previous studies showed that combination yield better results 
than mono-therapy and toxicities were not accelerated [3, 10]. However, combination 
therapy have yet to demonstrate clear cut and reproducible advantages in terms of 
remission rates [10]. 
 
Recent progresses in understanding cytokine networks in RA revolutionized 
the management of the disease. Since pro-inflammatory cytokines like IL-1, IL-6 
and TNF- are crucial for joint inflammation and destruction, blocking these 
cytokines appears to be practical strategies for RA therapy [3, 10]. Several biologics 
(antibodies or antagonist of IL-1, IL-6 and TNF-) had been approved for use in RA 
[3, 5, 9, 10]. The current arsenal of biologic agents is depicted in Table 1.1. Biologics 




have several advantages over conventional pharmacotherapy. They tend to work faster, 
inhibit joint destruction significantly and are less toxic compared to DMARDs [3, 5, 9, 
10]. Hence, these will help to improve patient well being, quality of life and function. 
However, high financial burden, increased infection risk, injection site reaction, 
lymphoma, heart failure and drug-induced autoimmunity were reported. As a result, 
the use of biologics is limited [3, 5, 9, 10]. In addition, more than 20% of RA patients 
do not respond to anti-TNF- therapy [10]. 
 
Table 1.1 The current arsenal of biologic agents  
Biologic [3, 5, 9, 10] Manufacturer Mechanism of action 
Abatacept (Orencia ®) Bristol-Myers Squibb CTLA4 immunoglobulin  
Adalimumab (Humira®) Abbott Laboratories TNF-α monoclonal antibody 
Anakinra (Kineret®) Amgen IL-1 receptor antagonist 
Certolizumab pegol 
(Cimzia®) 
UCB Pegylated Fab fragment of a TNF-α 
monoclonal antibody 
Etanacept (Enbrel®) Amgen and Wyeth TNF-receptor (p75)-Fc antagonist 
Golimumab (Simponi®) Centocor Ortho 
Biotech Inc. 
TNF-α monoclonal antibody 
Infliximab (Remicade®) Centocor Ortho 
Biotech Inc. 
TNF-α monoclonal antibody 
Rituximab (Rituxan®) Genetech Inc. CD20 antibody 
Tociluzumab(Actemra®) Roche IL-6 receptor antibody 
 
CTLA4, cytotoxic T lymphocyte antigen 4 




1.2 The Histone Code and HDAC Inhibitors 
In eukaryotes, DNA is wrapped around a histone octamer to form a 
nucleosome which is the basic structural unit of chromatin [11-13]. The amino ends of 
nucleosomes are subjected to a myriad of post-translational modifications [11-13]. 
The modifications include acetylation by histone acetyltransferases (HATs), 
deacetylation by histone deacetylases (HDACs), methylation by histone lysine 
methyltransferases, phosphorylation, poly-adenosine diphospate ribosylation, 
ubiquitinylation, sumoylation, carbonylation and glycosylation [11-13].  
 
The histone acetylation status controls gene expression as illustrated on Figure 
1.2 [11-13]. Acetylation of the -NH2 group on lysine residues within histone tails 
neutralizes the positive charge [11-13], loosening the chromatin to allow transcription 
factors to access the promoter regions of target genes [11-13]. On the other hand, 
deacetylating lysine residues on histone tails leads to chromatin condensation and 
transcription repression [11-13]. The participation of HATs and HDACs in gene 
expression control as well as applications of HDAC inhibitors in cancer treatment had 




Figure 1.2 The histone acetylation status controls gene expression – modified from 
McIntyre J, Moral MA, Bozzo J [12]. 
RNA pol II , RNA polymerase II; TF, transcription factor 




Eighteen HDAC enzymes have been identified in humans [11]. They are 
classified based on their homology to yeast HDACs, locality within cells and enzyme 
activities [11]. Class I HDACs (HDAC1, 2, 3 and 8) are homologous to yeast RPD3 
protein [11]. They are found in the nucleus and ubiquitously expressed in a number of 
human cells as well as tissues [11]. Class II HDACs (HDAC4, 5, 6, 7, 9, and 10) are 
homologous to yeast Hda1 protein and are able to shuttle between the nucleus and 
cytoplasm [11]. Class IIb HDACs (HDAC6 and 10) are found in the cytoplasm and 
have two deacetylase domains [11]. HDAC6 has specific substrate specificity to α-
tubulin [11]. Class III HDACs (Sirtuin or SIRT1, 2, 3, 4, 5, 6 and 7) are homologous 
to yeast silent information regulator two protein and are dependent on the redox status 
of the nicotinamide adenosine dinucleotide (NAD
+
) coenzyme to regulate gene 
expression [11]. Class IV HDAC’s sole member is HDAC11 [14].  
 
Carcinogenesis is a multi-step event [13] and studies revealed that HDACs 
play important roles in cancer development [11-13]. They had been reported to 
contribute to the pathogenesis of acute promyelocytic leukemia (APL), acute myeloid 
leukemia (AML) and B cell lymphoma. Aberrant recruitment of HDACs to promoters 
occurs when they associate or interact with oncogenic DNA-binding fusion proteins 
that result from chromosomal translocation or over-expression of repressive 
transcriptional factors [11]. Over-expression of certain HDACs had been reported in 
breast, cervical, colon, colorectal and gastric tumor samples [11]. HDAC inhibitors 
had been documented to be anti-neoplastic [11] by selectively inducing apoptosis in 
tumor cells via several mechanisms. For instance, HDAC inhibitors activate death 
receptor (extrinsic) and mitochondrial (intrinsic) death pathways, induce bcl-2 
homology (BH)-3 proteins to cause apoptosis, regulate reactive oxygen species 




production and induce cell cycle arrest [11]. In addition, HDAC inhibitors are anti-
angiogenic, anti-invasive and immuno-modulating [11]. Therefore, HDAC inhibitors 
appear to be rational anti-cancer therapies. It is not surprising that great interests are 
ignited in drug discovery programs, leading to the identification of numerous HDAC 
inhibitors. HDAC inhibitors are classified according to their chemical structure. There 
are benzamides, cyclic tetrapeptides, electrophilic ketones, hydrocarbons, short-chain 
fatty acids and miscellaneous [11].   
 
Over the past fifteen years, epigenetic regulation drew significant attention in 
the anti-cancer drug discovery arena leading to the development of HDAC inhibitors 
as innovative anti-cancer modalities. In October 2006, US Food and Drug 
Administration approved the first HDAC inhibitor – vorinostat (suberoylanilide 
hydroxamic acid or SAHA). It is indicated for cutaneous T-cell lymphoma (CTCL) 
[14-16]. At least twenty other HDAC inhibitors had entered Phase I clinical trials 
(Table 1.2). Besides being anti-neoplastic, HDAC inhibitors are promising anti-
inflammatory agents.  




Table 1.2 HDAC Inhibitors in clinical development 












OH mM [11, 12] Class I, IIa [12] 
Colorectal cancer: Phase I [224]; Epstein-Barr virus-associated 
lymphoid malignancies: Phase II [223, 226] 
 






Prodrug of butyric 
acid [12] 








Prodrug of butyric 
acid [227] 
Advanced or refractory solid tumors: Phase I [227]; Refractory 





mM [11, 12] Class I, IIa [12] 
Lung cancer: Phase I [226]; Neuronal tumors and brain 
metastases: Phase I [226]; Advanced Cancer: Phase I [226]; 
Advanced thyroid cancer: Phase II [226]; Ovarian cancer: 
Phase I and II [226]; Prostate cancer: Phase II [226]; Solid 
tumors: Phase I [226]; NSCLC: Phase I [226]; Locally 
advanced breast cancer: Phase II [226]; Glioblastoma 
multiforme: Phase II [226]; Small cell lung carcinoma: Phase 
II [226]; Leukemia and lymphoma: Phase II [226]; High grade 







mM [232] Class I, IIa [233] 
Refractory solid tumors: Phase II [219]; MSD: Phase I [220]; 
AML: Phase I [217, 220]; NHL: Phase I [216]; Brain tumor: 
Phase I [217] Relapsed or refractory Epstein-Barr virus-
positive cancer: Phase II [217]; Lymphoma: Phase I [217]  
 




Table 1.2 HDAC Inhibitors in clinical development – Continued 1 



























Class I (HDAC 1 
and 2)[247]; Class 
IIb (HDAC 6) 
[235] 
Gastrointestinal stroma cancer and sarcoma: Phase II [217]; 
Head and neck cancer: Phase II [217]; Peripheral T-cell 
lymphoma: Phase II [226]; Bladder cancer: Phase II [217]; 
Transitional cell cancer of the pelvis and ureter: Phase II 
[217]; Urethral cancer: Phase II [217]; Advanced lung, 
esophageal and pleural cancer: Phase I [217]; Locally 




















μM [236] HDAC 1 and 2 [236] 
Solid tumor: Phase I [221]; Lung cancer: Phase III [237]; 
Pancreatic cancer: Phase II [217], Multiple myeloma and 
















HDACs 1, 2, 3, 
and 8 (> 100 μM) 
[238] 
Solid tumor: Phase I [222]; Lymphoma: Phase I [222]; 
Lung cancer: Phase I and II [217]; Breast cancer: Phase II 
[217]; NSCLC: Phase II [217]; Renal cell carcinoma: Phase 
I and II [226]; ALL: Phase II [217]; AML: Phase II [217]; 
CML: Phase I [217];  HL: Phase II [217]; Hepatocellular 















Class I, IV 
[235, 239] 
Lymphoma: Phase II [226]; NSCLC: Phase I and II [226]; 
Advanced malignancies: Phase I [226]; Myelodysplastic 
syndrome: Phase I [226]; AML: Phase II [226] 
 




Table 1.2 HDAC Inhibitors in clinical development – Continued 2 











































Class I, IIa, IIb, 
IV [12, 231] 
CTCL: approved by FDA [15-16]; Ovarian cancer: Phase I 
and II [226]; Fallopian cancer: Phase II [226]; Peritoneal 
cancer: Phase II [226]; NSCLC: Phase I [226]; Pancreatic 
cancer: Phase I [226]; Melanoma: Phase I [226]; 
Lymphoma: Phase I [226]; Esophageal cancer: Phase I 
[226]; Gastric cancer: Phase I [226]; Liver cancer: Phase I 
[226]; Breast cancer: Phase I and II [226]; Pancreatic 
cancer: Phase I and II [226]; Stage III/IV squamous cell 
carcinoma of the oropharynx: Phase I [226]; Brain and 
central nervous system tumors: Phase I [226]; Small 















Class I, IIa, IIb, 
IV [12, 231] 
Advanced solid tumors: Phase I [242]; AML: Phase I [243]; 
MSD: Phase I [243];CLL: Phase I [243] 
 




Table 1.2 HDAC Inhibitors in clinical development – Continued 3 





















Class I, IIa, IIb, 
IV [12, 231] 
 Lung cancer: Phase I [226]; Head and neck cancer: Phase 
II [226]; Thyroid cancer: Phase II [226]; Breast cancer: 
Phase I [226]; Renal cell carcinoma: Phase I [226]; 
Metastatic renal cell carcinoma: Phase II [226]; Colorectal 
cancer: Phase II [226]; NSCLC: Phase I and II [226]; 
Prostate cancer: Phase I [226]; Small cell lung cancer: 
Phase I and II [226]; Esophageal cancer: Phase I [226]; 













unknown effect on 
other 
HDACs[245] 
















Class I, IIa, IIb, 
IV [12, 247] 
Ovarian cancer: Phase I and II [226]; Solid tumor: Phase I 
[226]; Lymphoma: Phase I [226]; Thymoma: Phase I amd II 
[226]; Small cell lung cancer: Phase I [226]; Liver cancer: 
Phase I and II [226]; Advanced hemotologic malignancies: 
Phase I [226]; Fallopian tube cancer: Phase II [226]; 
Peritoneal cavity cancer: Phase II [226]; Malignant 
mesothelioma: Phase II [226]; Cancer of unknown primary: 
Phase II [226]; AML: Phase II [226]; NHL: Phase II [226]; 
myelodysplastic syndromes: Phase II [226]; ALL: Phase I 











Table 1.2 HDAC Inhibitors in clinical development – Continued 4 






















Solid tumors: Phase I [226]; Hematologic 











µM [27] Class I, II [27] 

























Table 1.2 HDAC Inhibitors in clinical development – Continued 5 






















µM [249] Class I, II [249] 
NHL: Phase I and II [226]; Multiple myeloma: Phase I 



























µM [251] Class I, II [251] 
Advanced hepatocellular cancer: Phase II [226]; HL: 






Undisclosed Undisclosed Undisclosed 
Solid tumors: Phase I [226]; Hematologic 
malignancies: Phase I [226]; Prostate cancer: Phase II 
[226] 
 
ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; HL, Hodgkin’s lymphoma,  NHL, Non-Hodgkin’s 
lymphoma; NSCL, non small-cell lung cancer




1.3 Pharmacological Activities of HDAC Inhibitors in Inflammation 
 The anti-inflammatory activities of HDAC inhibitors had been reported 
extensively. For instance, butyrate resulted in improvement or remission of inflammatory 
bowel diseases (IBDs) [17, 18]. Crohn’s disease was ameliorated when butyrate was 
administered to patients as enteric coated tablets at 4 g/day over 8 weeks [17]. 
Combination of butyrate with conventional IBD medications like mesalazine helped to 
improve the efficacy of oral mesalazine in ulcerative colitis. It was observed that the 
combination achieved better improvement in ulcerative colitis disease activity index as 
compared to mesalazine alone (combination: 7.27 ± 2.02 to 2.58 ± 2.19, p < 0.05; 
mesalazine alone: 6.07 ± 1.60 to 3.46 ± 1.98, p < 0.05) [18]. The anti-inflammatory 
actions of butyrate were thought to be mediated by the suppression of pro-inflammatory 
cytokines like IL-1β and inhibition of nuclear factor-kappa B (NF-B) activation in 
macrophages [17-19]. In addition, SAHA and valproic acid (VPA) ameliorated dextran 
sulfate sodium- and trifluorobenzene sulfonic acid-induced colitis in mice. Their actions 
might be associated with the suppression of pro-inflammatory cytokines like IL-1β, IL-10, 
interferon (IFN)-γ and TNF-α as well as histone 3 hyperacetylation [20]. 
  
Beneficial effects with HDAC inhibitors were also noted in a pre-clinical 
systemic lupus erythematosus (SLE) model. Mishra et al found that SAHA and 
trichostatin (TSA) reduced glomerulonephritis, proteinuria (mean albumin secretion per 
day: 765 µg ± 350 µg to 94 µg ± 87 µg at 19 weeks, p < 0.05) and spleen weight (0.41 g 
± 0.06 g to 0.28 g ± 0.08 g at 19 weeks, p < 0.05) in MRL-lpr/lpr mice [21]. The anti-




SLE effects of the HDAC inhibitors were attributed to suppression of the mRNA and 
protein levels of pro-inflammatory cytokines like IL-6, IL-10, 1L-12 and IFN-γ as well as 
histone hyperacetylation [21]. 
 
Neuro-protective effects of HDAC inhibitors were observed when butyrate, TSA 
and VPA attenuated lipoplysaccharide (LPS)-induced pro-inflammatory responses as 
well as protected dopaminergic neurons from damages in mesencephalic neuron-glial 
cultures [22]. The phenomena were due to a reduction in the number of activated 
microglia [22]. Pro-inflammatory mediators like NO and TNF-α were almost completely 
suppressed at 3 hr and 24 hr, respectively [22]. The aforementioned demonstrated the 
potential utility of HDAC inhibitors in inflammation-related neurodegenerative disorders 
such as Parkinson's disease [22]. In rat stroke models, VPA administered 
intraperitoneally at 300 mg/kg twice daily, alleviated cerebral inflammation and peri-
hematomal cell death after intracerebral hemorrhage [23]. Such effects were achieved by 
inhibiting caspases, hematoma expansion and inflammatory cell infiltration [23]. VPA 
also activated acetylated histone 3 translation, up-regulated bcl-2 protein and down-
regulated IL-6 and MMP-9 mRNA levels [23]. VPA-treated rats showed better functional 
recovery from 1 day to 4 weeks after intra-cerebral hemorrhage [23]. In all, the anti-
inflammatory and neuro-protective effects offered by HDAC inhibitors were believed to 
be mediated by transcriptional activation following HDAC inhibition [23, 24].  
 




In other miscellaneous observations, TSA attenuated ovalbumin-induced airway 
inflammation in a mouse allergic asthma model [25]. TSA treatment was found to reduce 
airway hyper-responsiveness as well as the number of CD4
+
 T cells, eosinophils, 
lymphocytes and mucus occlusions in the bronchoalveolar lavage fluid [25]. Since there 
was less T cell infiltration, the expression of IL-4 and IL-5 in the bronchoalveolar lavage 
fluid was decreased [25]. TSA could also reduce spinal cord demyelination and 
inflammation, axonal and neuronal loss as well as ameliorate disability in the relapsing 
phase of experimental autoimmune encephalomyelitis (a model for multiple sclerosis) 
[26]. ITF-2357 administered orally at 1 or 5 mg/kg significantly reduced liver damage in 
a mouse concanavalin A-induced hepatitis model [27]. The level of alanine transferases 
were reduced by more than 80% upon treatment [27]. Hepatic protection could be in part 
due to the anti-inflammatory effects of ITF-2357 as it suppressed LPS-induced IFN-γ and 
TNF-α secretion by more than 50% at 6 hr after administration [27]. KBH-A42 inhibited 
the expression of IL-1β, IL-6, TNF-α and inducible nitric oxide synthase (iNOS) in a 
LPS-induced mouse endotoxemia model as a result of decreased p38 phosphorylation 
[28]. 
 
However, there were situations where HDAC inhibitors appeared to be pro-
inflammatory. For instance, TSA pretreatment enhanced IL-8 production in LPS-
stimulated SV-40-transformed lung epithelial cells, suggesting that TSA induced airway 
inflammation [29]. Reduced HDAC2 expression and activity had been reported in lung 
macrophages, biopsies and blood cells from patients with chronic obstructive pulmonary 




disease (COPD), severe and smoking asthma [30, 31]. HDAC inhibition would therefore 
further induce inflammatory gene expression in vitro [30, 31]. The pro-inflammatory 
activities of HDAC inhibitors in airway inflammation were found to be mediated through 
the interaction between HDAC2 and NF-κB [30, 31].  In addition, SAHA and TSA 
augmented LPS-induced inflammatory responses in murine N9 cells, rat primary 
microglial cells, hippocampal slice cultures and neural co-cultures [32]. Butyrate also 
enhanced LPS-induced inflammatory responses in N9 cells [33]. In contrast, butyrate was 
anti-inflammatory against LPS-induced responses in rat primary microglia, hippocampal 
slice cultures, neural co-cultures of microglial cells, astrocytes and cerebellar granule 
neurons [33]. It also suppressed IFN- in BV2 murine microglial cells but did not affect 
LPS-induced NO and TNF- secretion [34]. Therefore, it could be gathered that the 
stimuli and target cells could be determinants of anti-inflammatory or pro-inflammatory 














1.4 Anti-Rheumatic Activities of HDAC Inhibitors in Pre-Clinical RA Models 
IL-1, IL-6 and TNF- are cytokines that drive inflammation in RA [1, 2, 4]. They 
are present in large quantities in RA synovial fluid and tissues, working synergistically to 
stimulate synovial tissue effector functions including adhesion-molecule expression, cell 
proliferation, other cytokines, MMP and prostaglandin secretion (Figure 1.3 and Figure 
1.4). Transgenic mice expressing human TNF- spontaneously develop chronic, 
inflammatory and destructive poly-arthritis similar to human RA [35]. Intra-articular IL-1 
injections led to cartilage degradation in rabbit knee joints while administering IL-1 
antibodies ameliorated mouse CIA and decreased cartilage damage [36]. Moreover, anti-
IL-1 and -TNF- biologics are approved for RA management (Figure 1.2), with more in 





































Figure 1.4 Effects of IL-6 – modified from Naka T, Nishimoto N, Kishimoto T [37].  
 
In a pilot study, Leoni et al reported that the oral administration of SAHA 
suppressed LPS-induced IL-1, IL-6, IFN- and TNF- in mice [38]. Similarly, SAHA 
suppressed LPS-induced IL-1, IL-12, IFN- and TNF- in human peripheral blood 
mononuclear cells [38]. The mRNA levels of IFN- and TNF- in these cells were also 
decreased [38]. Since IL-1 and TNF- play pivotal roles in RA pathogenesis and anti-
IL-1 or TNF- biologics exhibit potent clinical efficacy in RA [1-5, 9], Leoni’s work 
prompted further investigation into the anti-rheumatic activities of HDAC inhibitors. 
 
Anti-rheumatic activities of HDAC inhibitors were observed to be almost always 
accompanied by the suppression of pro-inflammatory cytokines like IL-1, IL-6 and TNF-
 [39-41]. In a rat AIA model, immunohistochemical analyses and northern blots 
indicated that synovial TNF- was inhibited by topical PB (200 mg/paw) and TSA (100 
mg/paw) which were applied twice daily for 18 days either with a prophylactic or 
therapeutic intent [42]. Similarly, in a mouse AMA model, a single intravenous dose of 




FK-228 at 2.5 mg/kg markedly reduced IL-1 and TNF- in synovial tissues [39]. 
Circulating IL-1 and IL-6 were also observed to be suppressed by FK-228 and TSA in 
mouse CIA model [41].  Prophylactic SAHA intervention administered subcutaneously at 
50 mg/kg, 5 doses weekly, decreased serum IL-1β and IL-6 by 33% and 40%, 
respectively. However, these observations were not considered to be statistically 
significant [41]. MS-275 administered subcutaneously at 3 and 10 mg/kg, 5 doses weekly, 
led to a significant reduction of IL-1β by 65 and 70% as well as that of IL-6 by 59 and 
93%, respectively [41]. In experimental asthma, hepatitis, IBD, SLE and stroke models, 
the anti-inflammatory activities of HDAC inhibitors were also accompanied by pro-
inflammatory cytokine suppression [17, 18, 21, 23-25, 27].   
 
In addition, synovial fibroblasts play important roles and work actively to drive 
joint destruction in RA [2, 4] by releasing pro-inflammatory cytokines. The cytokines 
cause synovial inflammation which is pivotal for disease development [1, 2, 4]. Hence, it 
was of interest to determine if HDAC inhibitors can modulate cytokine production in 
monocytes and RASFs. There had been evidence to demonstrate that synovial fibroblasts 
are key players in initiating and driving joint destruction in RA [1, 2]. RASFs appear 
different from normal synovial fibroblasts or those from OA patients [1, 2]. RASFs found 
in synovial lining, had been shown to generate MMPs in response to various extracellular 
signals such as cytokines, growth factors and matrix molecules [1-2]. On their own, 
RASFs can also secrete cytokines like IL-6 [1-2]. Such pro-inflammatory mediators then 
stimulate MMPs to degrade type II collagen and aggregans which are the major 




components of the ECM [1-2]. Therefore, RASFs have emerged as an important 
therapeutic target in the treatment of RA [1-2]. It is interesting to note that while RASFs 
may be different from normal synovial fibroblasts or those from OA patients, they share 
several common characteristics with malignant tissues. Both of which possess anchorage-
independent growth, loss of contact inhibition, oncogene activation, monoclonal or 
oligoclonal expansion, detectable telomerase activity and somatic gene mutations [1]. 
Since HDAC inhibitors were originally developed as anti-cancer agents, a possibility of 
their application in RA exists. 
 
In eukaryotes, cell proliferation is dependent on cell cycle progression which is 
tightly regulated by the periodic synthesis and removal of cyclins that associate with and 
activate CDKs [43]. CDK inhibitors such as p16, p21 and p27 play important roles in cell 
cycle control [43] by coordinating internal or external signals and impeding proliferation 
at several key checkpoints [43-46].  
 
Synovial hyperplasia and panus formation are associated with RA [1, 2]. The 
hypertrophic and invasive nature of RASFs could in part be due to p16, p21 and p27 
impairment as deficiencies in CDK inhibitors were often observed to result in increased 
cell proliferation and hyperplasia [47, 48]. It was demonstrated that deficiencies in these 
CDKs inhibitors led to increased cell proliferation thereby RA synovial hyperplasia [47, 
48]. In one study, loss of p21 was also associated with SLE [49]. Ominously, p21 down-




regulation is often observed in RASFs [50]. As a consequence of p21 down-regulation, 
there was excessive joint invasion and subsequent destruction [51].  
 
On the other hand, p21 over-expression in RASFs via viral transfection led to 
resolution of inflammation and inhibition of proliferation [52]. Forced expression of p21 
in the synovial tissues was effective in treating arthritis in animal models [52]. The 
inhibitory effect of p21 on cell cycle progression was evidenced by reduced synovial 
hyperplasia [52]. In addition, lymphocyte infiltration, expression of pro-inflammatory 
cytokines (IL-1, IL-6 and IL-8) and bone and cartilage destruction were inhibited [52]. 
The down-regulation of IL-1R1 by p21 also resulted in attenuated responsiveness to IL-1 
[52]. Such anti-inflammatory activities were attributed to p21 gene transfer which down-
regulated the expression of various pro-inflammatory mediators and tissue-degrading 
proteinases involved in RA pathogenesis [52]. At the same time, there was reduced c-Jun 
N-terminal kinase activity as a result of NF-κB and activator protein (AP)-1 inhibition 
[52]. Hence, multiple regulatory pathways might work in concert to inhibit cell cycle 
progression to ameliorate arthritis [52]. It seemed that a relationship between CDK 
inhibitor genes and inflammatory molecules existed. Besides, in vivo efficacy studies of 
p16 and p21 gene therapies had been documented in rodent arthritis models [52, 53]. 
Therefore, modulating CDK inhibitors can potentially alter inflammatory responses. 
 
The first proof of concept study was published in 2003 where Chung et al 
discovered that phenylbutyrate (PB) and TSA inhibited the proliferation of synovial 




fibroblasts isolated from rats with adjuvant-induced arthritis (AIA) in a dose-dependent 
manner (DNA synthesis: PB IC50 ≈ 2 mM, TSA IC50 ≈ 100 nM) [42]. Proliferation 
inhibition was not due to nonspecific cytotoxicity but attributed to up-regulation of p16 
and p21 cell cycle inhibitors [42]. The inhibition was irreversible as RASFs could not 
proliferate as well as their normal counterparts when the HDAC inhibitors were 
withdrawn. When the noxious agent was removed, p21
WAF/Cip1
 expression was reduced in 
both cell types, but p16 remained up-regulated [36]. In addition, RASF growth inhibition 
occurred at 12 hr upon exposure to the HDAC inhibitors while normal cells took 24 hr to 
respond [42]. PB and TSA also resulted in senescence in RASFs but not in normal cells 
[42]. p21 was elevated by 2-folds at 2 hr but fell to levels in cultures without FK-228 at 
24 hr. p16 was increased by 4.5-folds at 2 hr and decreased at 24 hr. However, the levels 
were still higher compared to cultures without FK-228. Similarly, FK-228 (IC50: 10 – 100 
nM) suppressed RASF proliferation in vitro [54]. Observed growth arrest was not due to 
non-specific cytotoxicity as most of the RASFs treated with FK-228, PB and TSA 
remained viable [42, 54]. It was postulated that the HDAC inhibitors caused growth 
arrest by up-regulating cell cycle inhibitors like p16
 
and/ or p21 via CDK pathways [42, 
54].  
 
The in vivo prophylactic efficacies of PB and TSA were also documented in the 
same model [42]. Topical PB cream (200 mg/paw) and TSA ointment (100 mg/paw) 
reduced joint swelling, sub-intimal mononuclear cell infiltration, synovial hyperplasia, 




panus formation as well as cartilage and bone destruction. TNF- expression was also 
reduced in affected tissues [42].  
 
The effect of TSA on TNF-related apoptosis-inducing ligand (TRAIL)-induced 
apoptosis was subsequently investigated in RASFs [55]. TSA and TRAIL co-treatment 
induced apoptosis in RASFs in a synergistic and dose-dependent manner whereas TSA or 
TRAIL alone had minimal or nil effects on RASF apoptosis [55]. TSA had induced cell 
cycle arrest in RASFs by up-regulating p21 [55]. In addition, the level of soluble TRAIL 
was significantly higher in RA than osteoarthritis (OA) synovial fluids [55]. Hence, it 
was concluded that TSA sensitized RASF for TRAIL-induced apoptosis [55]. It was 
touted to represent a new principle for the treatment of RA. 
 
Anti-arthritic effects were also demonstrated when TSA was combined with low-
intensity ultrasound (0.2 W/cm
2
) in the presence of microbubbles in human RASFs [56]. 
In a dose-dependent manner, 0.1 μM of TSA alone was able to reduce cell viability, 
induce G0/G1 phase arrest and apoptosis [56]. The aforementioned cell cycle arrest 
occurred as a result of p21
 
up-regulation at 6 hr and cyclin A, B and D down-regulation at 
24 hr [56]. Ultrasound treatment in the presence of microbubbles increased cellular 
uptake but did not induce cell cycle arrest or apoptosis [56]. From a microarray analysis, 
it was shown that combination of TSA with low-intensity ultrasound modulated gene 
expression profile and enhanced the anti-inflammatory effects of TSA in RASFs [56].  
Consequently, there was reduced mRNA expression of inflammatory genes such as IL-6, 




IL-15, IL-18, a disintegrin and metalloproteinase with thrombospondin motifs 
(ADAMTS)-5, cathepsin L (CTSL), granulocyte macrophage-colony stimulating factor 
(GM-CSF), MMP-2 and vascular cell adhesion molecule (VCAM-1) [56].  
 
As mentioned earlier, histone acetylation loosens the chromatin. The loosening of 
the chromatin will allow various transcription factors to access promoter regions of target 
genes to facilitate gene transcription. Among the genes that are consistently up-regulated 
because their promoters are associated with acetylated histones, is the p21 protein [12, 
13]. p21 inhibited cell cycle progression by blocking CDK activities and inducing G1 
phase arrest [12, 13]. HDAC inhibitors had been shown to induce p16 and p21 in RA-
related models [12, 13]. For instance, FK-228, PB and TSA could up-regulate p16 and 
p21 in RASFs [42, 54]. The in vivo anti-rheumatic efficacy of PB and TSA was 
accompanied with p16 and p21 induction or up-regulation [44, 52]. Following the 
induction of these cell cycle regulators, the expression of pro-inflammatory cytokines like 
IL-1β and TNF-α were reduced [44, 52]. The results indicated the potential utility of 
HDAC inhibitors as anti-rheumatic agents. Therefore, it is hypothesized that HDAC 
inhibitors exert their anti-proliferative effects by inducing or up-regulating CDK 


















Figure 1.5 HDAC inhibitors inhibit cell proliferation by modulating CDK inhibitors 
 
More recently, it was found that HDAC inhibitors like TSA and nicotinamide 
could influence the activation of macrophages derived from the inflamed joints of RA 
patients [56]. The inhibition of class I and class II HDACs or class III sirtuin HDACs 
suppressed LPS-induced IL-6 and TNF-α from macrophages in healthy donors and RA 
patients [57]. The mRNA levels of the respective cytokines were also reduced [57]. TSA 
and nicotinamide also induced macrophage apoptosis by specifically down-regulating 
anti-apoptotic protein Bfl-1/A1 as well as enhancing the sensitivity of the macrophages to 
HDAC inhibitor-induced apoptosis [57]. As a result, the production of inflammatory and 
angiogenic cytokines and chemokines such as IL-6, IL-23, CCL-2, CCL-5 and CXCL-12 
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The chondro-protective effects of TSA were confirmed by Nasu and co-workers 
in collagen-induced arthritis (CIA) mice [53]. TSA was able to ameliorate the severity of 
the disease and inhibited synovial inflammation and cartilage destruction [53]. 
Immunohistochemistry analyses showed that TSA treatment dramatically reduced the 
number of MMP-3 and MMP-13 positive chondrocytes [53]. In addition, IL-1β and TNF-
α-stimulated MMP-3 production in murine ATDC5 chondrogenic cells was suppressed 
[53]. TSA was also found to antagonize the effects of fibroblast growth factor (FGF)-2 
and IL-1β on MMP expression in human articular chondrocytes [58]. Hence, TSA could 
decrease both anabolic and catabolic genes, slowing down cartilage turnover [58].  
 
Clinically approved HDAC inhibitors like VPA are exciting avenues to explore as 
they are easily accessible and there is experience with handling. It had been shown that 
VPA administered intraperitoneally at 400 mg/kg daily for 21 days decreased the 
incidence and severity of CIA in mice [39]. The incidence of CIA was 31% in the VPA-
treated group as compared to 79% in the control group (p < 0.005) [39]. In addition, the 
mean clinical disease severity was reduced by 92% (p < 0.03) [439]. Histological sections 
from VPA-treated mice revealed well-preserved joints with little inflammation, synovial 
hypertrophy, cartilage damage or bone destruction [39]. It was also observed that VPA 
increased acetylation of proteins from splenocytes of CIA mice. In addition, the 
regulatory T cells (Tregs) derived from the VPA-treated group inhibited the proliferation 
of CD4
+
 T cells better than the control group [39]. Hence, the joint protective effects of 
VPA were believed to be due to elevated Treg function [39]. 




Another group confirmed the anti-rheumatic activities of FK-228 in a rat AIA 
model [41]. As prophylaxis, FK-228 suppressed AIA development and decreased its 
severity in a dose-dependent manner [41].  FK-228 administered intravenously at 0.5 
mg/kg twice weekly completely inhibited AIA onset [45]. Histological analyses revealed 
less inflammation and bone destruction [41].  
 
The in vivo anti-rheumatic activities of two clinically active HDAC inhibitors, 
MS-275 and SAHA, were tested in rodent CIA models [59]. SAHA administered 
subcutaneously to mice at 5 mg/kg and 50 mg/kg or orally to rats at 15 mg/kg and 50 
mg/kg, 5 doses weekly, exhibited moderate prophylactic efficacy but could not inhibit 
CIA onset [46]. However, it alleviated joint swelling and bone erosion in both mice and 
rats as well as slightly reduced bone resorption accelerated by arthritis in rats [59]. High-
dose MS-275 administered to mice subcutaneously at 10 mg/kg or to rats at 3 mg/kg, 5 
doses weekly, exhibited good prophylactic efficacy by preventing bone erosion and 
markedly delaying CIA onset [59]. Low-dose MS-275 administered to mice 
subcutaneously at 3 mg/kg or to rats at 1 mg/kg, 5 doses weekly, attenuated joint swelling, 
bone erosion and resorption [59]. The anti-rheumatic activities of MS-275 were then 
confirmed by histology [54]. Synovial hyperplasia, panus formation as well as cartilage 
and bone destruction were not observed in mice treated with high prophylactic doses of 
MS-275 [59]. In addition, there were decreased sera levels of IL-1 and IL-6 [59]. The 
therapeutic efficacy of MS-275 administered subcutaneously to rats at 5 mg/kg daily was 




confirmed when it stopped disease progression and joint destruction after CIA onset [59]. 
Hence, MS-275 could be more potent than MTX [59].  
 
NF-қB is a group of transcription factors that is involved in the induction and 
repression of gene expression by binding to қB elements on DNA [1, 60]. It is implicated 
in inflammatory cascades that encompass a plethora of genes in RA (Figure 1.6). The 
genes encode for cytokines, MMPs and regulators of small-molecule mediators. NF-қB 
suppression offered benefits in various animal inflammatory disease models [1]. In 
addition, many clinically active DMARDs (gold, leflunomide and sulfasalazine), aspirin 




Figure 1.6 Involvement of the NF-κB signaling pathway in RA – modified from 
Okamoto T [61].  
 




It had been proposed that the anti-inflammatory activities of HDAC inhibitors 
might be mediated through NF-κB inhibition [60]. To illustrate this point, the inhibitory 
effects of HDAC inhibitors on NF-қB activation had been reported in various in vitro 
cancer models. SAHA and TSA down-regulated TNF- receptor (TNFR)-1 expression as 
well as surface exposure in A549 and NCI-H460 lung cancer cell lines. As a result, there 
was reduced phosphorylation and activation of TNF--induced inhibitor kappa kinase 
(IKK). As IKK is a NF-қB activator, reduced phosphorylation and activation attenuated 
NF-қB DNA binding [62]. In turn, NF-κB nuclear translocation was impeded [62].  
Takada et al reported that SAHA inhibited NF-қB and target gene expression [63]. NF-
қB inhibition could enhance apoptosis as well as reduce joint invasion and 
osteoclastogenesis [64]. In addition, TSA down-regulated cyclin D1 transcription by 
inhibiting NF-қB p65 DNA binding  [63]. Exposure to 1 mM of butyrate or 1.5 M of 
SAHA for 24 hr resulted in marked decreases in NF-қB DNA binding in U937 cells  [63].  
Butyrate also inhibited TNF--induced nuclear translocation of NF-қB in HT-29 cells 
[64]. KBH-A42 suppressed LPS-induced IL-1β, IL-6, TNF-α and iNOS expression in 
RAW264.7 cells as well as in a mouse endotoxemia model [28]. It was proposed that the 
inhibition of these pro-inflammatory cytokines occurred as a result of modulation in NF-
κB DNA binding since NF-κB is significantly involved in the expression of pro-
inflammatory mediators like interleukins, iNOS and TNF-α [1, 28]. Surprisingly, NF-κB 
DNA binding was not observed to be affected by KBH-A42 [28]. Instead, the DNA 
binding of another transcription factor AP-1 was decreased with KBH-A42 treatment 
[28]. 




Despite the ability of HDAC inhibitors to inhibit NF-κB, it should be noted that 
NF-κB activation by HDAC inhibitors had also been reported. In head and neck 
squamous cell carcinoma, butyrate and TSA enhanced NF-κB activation, conferring 
cancer cells resistance to HDAC inhibitors [63].  HeLa cells also developed resistance to 
apoptosis when treated with apicidin due to increased NF-κB transcription activity [65]. 
The pro-inflammatory activities of HDAC inhibitors in COPD were also linked to NF-қB 
[30]. Glucocorticoids are important therapeutic agents for many chronic inflammatory 
diseases in spite of their well known side effects [30]. Although COPD presents as a 
chronic inflammatory lung disease, glucocorticoids purportedly do not work well for the 
condition [30, 31]. Adcock et al reported HDAC2 as an important co-repressor molecule 
for glucocorticoid-mediated suppression of NF-κB-driven inflammatory gene expression 
in human lung epithelial cells and macrophages (Figure 1.7) [30]. HDAC2 achieves the 
suppression of NF-κB-driven inflammatory gene expression by reducing ligand-induced 
glucocorticoid receptor K494/K495 acetylation [30]. Given the inactivity of 
glucocorticoids in COPD, it is not surprising that reduced HDAC2 expression and 
activity were observed in lung macrophages and tissues from COPD patients [30, 31]. 
Furthermore, it was found that HDAC2 over-expression in glucocorticoid-insensitive 
alveolar macrophages of COPD patients was able to restore the sensitivity to 
glucocorticoids [30, 31]. The findings implied that reduction in HDAC2 activity played a 
critical role in glucocorticoid insensitivity by repressing NF-κB-mediated inflammatory 
gene expression. The aforementioned highlighted the potential of HDAC activators as 
enhancers of glucocorticoid function. Similar mechanisms also resulted in steroid 




resistance observed with latent adenovirus infections [636]. Theophylline was able to 
restore the reduction in HDAC activities and  reverse  steroid resistance in COPD as well 
as other inflammatory diseases [66]. As HDAC2 is critical for turning off pro-





Figure 1.7 HDAC2 as an important co-repressor molecule for glucocorticoid-mediated 
suppression of NF-κB-driven inflammatory gene expression – modified from Adcock IM, 
Tsaprouni L, Bhavsar P, Ito K [30].  
GR, glucocorticoid receptor 
 
Contradictorily, TSA attenuated ovalbumin-induced airway inflammation in a 
mouse allergic asthma model [25]. The ‘epigenetics of’ in such specific disease models 
remains unknown. Furthermore, HATs and HDACs have non-histone targets. The anti-




inflammatory activities of TSA in an ovalbumin-induced allergic asthma model could be 
mediated via non-histone protein acetylation.  
 
It is identified that the impact of HDAC inhibitors on NF-қB has never been 
assessed in RA-related cells or tissues. It will be important to determine whether HDAC 
inhibitors exhibit anti-rheumatic activities via the inhibition of the NF-қB signaling 
pathway. Recently, it had been shown that NF-қB can be subjected to post translational 
modifications, including reversible acetylation. Such a process has been deemed as an 
intra-nuclear molecular switch that controls NF-қB actions dynamically. However, little 
is known about the impact of acetylation status on NF-қB functions. However, HDAC 
inhibitors may suppress NF-ĸB signaling pathway and subsequently the downstream 
processes controlled by the NF-κB signaling pathway such as NO and pro-inflammatory 
cytokine, chemokine, VEGF and MMP secretion. 
 
RA represents a challenge for therapeutic interventions due to the complex 
inflammatory signaling pathways underlying its pathogenesis. Besides the NF-κB 
signaling pathway, the MAPK signaling network is another attractive therapeutic target 
as it is one of the major effector limbs in inflammation [67-70]. The MAPK family 
comprises of highly conserved serine/threonine
 
protein kinases which are involved in 
regulation
 
of gene induction, cell survival, apoptosis,
 
proliferation and differentiation as 
well as cellular stress
 
and inflammatory responses [67-70].  
 




In mammals, there are three major MAPK classes. They are the extracellular 
signal-regulated kinases
 
(ERKs) and two stress-activated protein kinase (SAPK) 
families–JNK and p38 [67-70]. MAPK stimulation requires the activation of a MAPK 
kinase (MKK) and a MAPK kinase
 
kinase (MKKK) upstream [67-70]. MKKKs are 
serine/threonine
 
protein kinases that phosphorylate and activate MKKs [67-70]. 
 
MKKs 
are threonine/tyrosine protein kinases that phosphorylate and activate MAPKs [67-70]. 
MAPK activation leads to the phosphorylation of cytoplasmic and nuclear proteins 
including various
 
transcription factors like AP-1, cyclic AMP-dependent transcription 
factor-1 and -2, signal transducer and activator of transcription (STAT)-1, Myc-
associated factor X complex, myocyte enhancer factor-2 and ELK1 to alter gene 
expression [71-90] (Figure 1.8). Interaction with these transcription factors is a crucial 
determinant of cellular responses after MAPK activation [71-90].  
 






Figure 1.8 The MAPK signaling pathway – modified from Kabbrah O and Chin L [90].  
 
MAPKs are important in RA because they control the production of cytokines like 
IL-1, IL-6, IL-8 and MMPs that destroy the ECM [92]. Several MAPKs are activated in 
RA [93]. p38, in particular, is thought to play a crucial role in RA synovial inflammation 
[93]. p38 is expressed in the RA synovial initimal lining [93] together with MKK3 and 6, 
which are the upstream kinases that regulate it [94].  MKK3 was also found to be the 
dominant MKK that controls p38 in fibroblast-like synoviocytes after TNF-α stimulation 
[94]. So far, four isoforms (α, β, γ and δ) of p38 had been identified [81, 94] with 
activation of the α-isoform being the most important for RA development [89].  The α-




isoform was also found to be particularly essential for cytokine regulation in 
macrophages [94]. In fact, MAPKs had been implicated
 
as key regulators of pro-
inflammatory cytokines  such as IL-1, IL-6,
 
IL-12, IL-23 and TNF-α as well as signal 
regulation of these same cytokines via the B cell receptor, T cell receptor, toll-like 
receptor (TLR), IL-1, IL-17 and TNFR
 
[64-67, 91-97]. Of relevance to RA, MKK3 and 
p38 were linked to NF-κB-mediated DNA binding and IL-6 production in synoviocytes 
[92].  
 
In view of the regulatory role of p38 on cytokine production as well as their 
ability to act as intracellular messengers for these cytokines, specific inhibitors were 
synthesized [95]. p38 inhibitors had been demonstrated to be effective in rodent models 
of arthritis [96, 97]. There was reduced inflammation due to corresponding decreases in 
IL-1, IL-6 and receptor of NF-κB ligand (RANKL) [96]. HDAC inhibitors like KBH-A42 
was shown to suppress the expression of pro-inflammatory cytokines like IL-1β, IL-6, 
TNF-α and iNOS in vitro in RAW264.7 cells as well as in vivo in a mouse endotoxemia 
model [28]. The anti-inflammatory effects of KBH-A42 were attributed to the decrease in 
p38 phosphorylation [28]. In addition to pro-inflammatory cytokine regulation, p38 could 
also affect synovitis by modulating cell cycle, apoptosis, neutrophil activation and 
oxidative processes by inducing NOS [97]. 
 
NO is a gaseous free radical synthesized via L-arginine oxidation by a family of 
NOS [71, 72]. In RA, NO serves as a pro-inflammatory chemokine [73, 74]. Nitrite, 




nitrate and degradation products of NO were observed to be elevated in the serum, 
synovial fluid and urine of RA patients [68, 69]. iNOS is also expressed in RA synovial 
tissues and chondrocytes [73, 74]. NO augments vascular permeability in inflamed 
tissues, generates destructive free radicals, induces cyclooxygenase (COX), angiogenic 
and inflammatory cytokines as well as activates MMPs [79].  
 
The anti-rheumatic activities of iNOS inhibitors had been demonstrated in rodent 
AIA and CIA models [80]. Hence, NO suppression may be beneficial for RA 
management.  For instance, HDAC inhibitors like butyrate, SAHA and TSA suppressed 
IL-1, IFN- and LPS-induced NO secretion as well as iNOS expression in  a variety of 
cell types [34, 38]. In fact, the inhibitory effects of HDAC inhibitors on NO secretion and 
iNOS expression correlated well with their anti-inflammatory activities in the respective 
studies [34, 38]. However, HDAC inhibitors may also work as pro-inflammatory agents.  
For instance, they enhanced LPS-induced NO secretion and iNOS expression in 
microglia cells [32, 33]. Therefore, the impact of HDAC inhibitors on NO secretion and 
iNOS expression was largely dependent on their roles in inflammation. HDAC inhibitors 
suppressed NO secretion and iNOS expression when working as anti-inflammatory 
agents whereas they enhanced NO secretion and iNOS expression when acting as pro-
inflammatory agents.  
 
HDAC inhibitors might also suppress NO by modulating NF-B and p38 MAPK 
signaling pathways. The suppressive effects of HDAC inhibitors on pro-inflammatory 




cytokines like IL-1, IL-6 and TNF- could further contribute to NO inhibition as iNOS is 
expressed only after exposure to these inflammatory mediators [72, 73]. It was of interest 
to investigate the effects of HDAC inhibitors on iNOS and NO secretion in RA-related 
cells such as RASFS and macrophages. 
 
In RA, there is progressive proteoglycan loss due to invasion of the panus into the 
joint space that eventually leads to cartilage damage [89]. A prerequisite for this event to 
occur is the production of MMPs [98, 99]. MMP production could also be controlled by 
p38, suggesting that p38 blockade confers structural benefits in RA [98, 99]. Indeed, p38 
inhibitors fared well in animal arthritis models whereby they effectively reduced cartilage 
destruction [96]. However, it was unclear if the aforementioned effect was due to direct 
inhibition on MAPK or indirect inhibition on pro-inflammatory cytokines like IL-1, 
which is the main inducer of MMPs [95]. 
 
Bone destruction and erosion is one debilitating aspect of RA that leads to 
structural damage and joint function loss [91]. Early cartilage damage and bone erosion is 
associated with panus formation [4].  Type B synoviocytes in the panus are key 
contributors for cartilage damage [1, 2]. The panus invades the joint space, digests ECM 
and subsequently destroys articular structures [1, 2]. At the same time, pro-inflammatory 
cytokines IL-1 and TNF- stimulate the expression of adhesion molecules on endothelial 
cells and increase neutrophil recruitment into the joints [4]. Neutrophils then release 
enzymes that degrade proteoglycan in superficial layers of cartilage, allowing immune 




complexes to precipitate and expose the chondrocytes [4]. In response to IL-1, TNF- 
and activated CD4
+
 T cells, chondrocytes and RASFs release MMPs [4].  
 
Bone erosion and destruction are radiographic hallmarks of RA which are 
mediated predominantly by osteoclasts [10]. Differentiation, maturation and activation of 
osteoclasts require signal transduction through a receptor, RANK, which engages a 
ligand, RANKL, on osteoblasts, fibroblasts and T cells [10]. RANKL can be induced by 
pro-inflammatory cytokines such as IL-1 and TNF-. Therefore, interfering with 
osteoclast activation can potentially prevent RA joint damage [10]. 
 
Since HDAC inhibitors could inhibit RASF proliferation at non-cytotoxic levels, 
joint destruction due to panus invasion could potentially decrease.  HDAC inhibitors also 
suppressed pro-inflammatory cytokines such as IL-, IL-6, and TNF- leading to 
decreased MMP expression. Although the impact of HDAC inhibitors on MMP 
expression has not been investigated in synovial fibroblasts, their suppressive effects had 
been reported in chondrocytes and cancer models [100]. 
 
In addition, as HDAC inhibitors were able to suppress IL-1 and TNF-, bone 
destruction by osteoclasts could decrease. In RAW264.7 cells, butyrate and TSA 
selectively suppressed osteoclastogenesis but did not affect their differentiation into 
macrophages [101]. Similarly, FK-228 inhibited osteoclastogenesis and reduced bone 
destruction in an AIA model [39]. It occurred via induction of interferon-β (IFN-β) which 




is an osteoclastogenesis inhibitor [39]. However, the inhibition was reversible by 
administering IFN-β antibodies [39]. TSA could also induce apoptosis in mature 
osteoclasts through p21 up-regulation [65]. 
 
Taken together, the protective effects of HDAC inhibitors against joint 
destruction might rely on pro-inflammatory cytokine suppression and osteoclast 
inhibition. HDAC inhibitors had been shown to suppress pro-inflammatory cytokines in 
monocytes and RASFs in earlier studies. Hence, it was of interest to determine if they can 
modulate MMP expression. Inhibition of cartilage damage and bone destruction by 
HDAC inhibitors is summarized in figure 1.9. 
 
Figure 1.9 Inhibition of cartilage damage and bone destruction by HDAC inhibitors 
 
The process is mainly controlled by osteoclasts [91, 102-104]. p38 activation is 





Pre-osteoblast Multi-nucleated cell 
Progenitor cell 
CD11b 




and TNF-α which are stimulants for hematopoietic precursor cells to differentiate into 
osteoclasts [105, 106]. Indeed, it had been demonstrated in experimental arthritis that p38 
blockade dramatically reduced osteoclast precursors and mature osteoclasts in the 
synovial tissues [96]. Consequently, tissue invasion of the juxta-articular bone was 
abrogated [99]. However, contradicting results had also been observed with p38 blockade 
in TNF-α-challenged CD44 knockout mice whereby increased osteoclast formation and 
bone resorption were observed [107]. Besides an increase in number, the osteoclasts were 
also bigger in size [107]. The increase in osteoclast number and size was attributed to 
decreased expression of MAPK phosphatase (MKP)-1 which is the regulatory molecule 
for p38 [107].  
 
VEGF also depends on p38 to communicate mitogenic stimuli to endothelial cells 
in order for neo-vascularization to occur in the panus [108]. VEGF is a potent angiogenic 
stimulus [108] hence it is likely that p38 can influence angiogenesis. Angiogenesis has 
been implicated in diabetic retinopathy, psoriasis, tumor growth and metastasis as well as 
RA [2, 109]. It is particularly active in early RA to supply oxygen and nutrients to the 
hypertrophic synovium. It also serves as a means of recruiting inflammatory cells to 
affected joints [2]. In pre-clinical rodent models, decreased angiogenesis reduced RA 
severity [10, 109, 110]. Many clinically used DMARDs like gold, MTX and sulfasalazine 
exhibit anti-angiogenic effects when given alone or in combination [109, 110]. Therefore, 
angiogenesis inhibition might be beneficial in RA [10, 109, 110].  
 




In a rheumatic joint, hypoxia aggravates inflammatory responses by increasing 
IL-1-dependent COX-2 expression [111]. Angiopoietin-1 is expressed in RASFs in 
response to hypoxia [112]. The augmentation of angiopoietin-1 was thought to be due to 
TNF-α, mediated by NF-κB [113]. It had been discovered that class II HDAC 4 and 6 
were associated with Von Hippel Lidau (VHL)-independent regulation of hypoxia 
inducible factor-1α (HIF-1α). LAQ824 inhibited HIF-1α dose-dependently to inhibit 
tumor angiogenesis. This involved acetylation and polyubiquitination by HDAC 
inhibitors [114]. Hydroxamic acid related compounds with class I and II HDAC activities 
were able to inhibit HIF-1α even at nanomolar concentrations. LBH589 was shown to 
inhibit endothelial tube formation at non-cytotoxic levels in pre-clinical studies [114]. 
Taken together, HDAC inhibitors with specific activities against class II HDAC isoforms 
might be effective inhibitors of HIF-1α and angiogenesis.  
 
VPA is a conventional anticonvulsant and mood-stabilizing agent. It was shown 
to be anti-angiogenic at millimolar levels in vitro and in vivo by inhibiting endothelial 
migration, proliferation and tube formation [115, 116]. The aforementioned effects were 
attributed to histone hyperacetylation and decreased endothelial NOS (eNOS) expression 
in chicken chorioallantoic membrane and mice Matrigel assay [115]. In a similar fashion, 
butyrate and TSA suppressed eNOS but angiogenesis was reversible by administering 
exogenous NO though not VEGF [117].  
 




HDAC inhibitors could also inhibit pro-angiogenic VEGF and kinase insert 
domain receptor expression [118]. On the other hand, anti-angiogenic VHL and 
neurofibromin-2 were induced [118]. In this manner, FK228 reduced hypoxia-induced 
angiogenesis at the same concentration in which it inhibited cellular HDAC activities 
[118]. FK-228 exposure for up to 24 hr also reduced IL-1β and TNF-α-stimulated 
expression of HIF-α and VEGF mRNA in RASFs in a dose-dependent manner [54]. It is 
interesting to note that a concentration of 5 nM was sufficient to generate such a 
phenomenon [40]. A single dose of FK-228 administered intravenously at 2.5 mg/kg was 
able to reduce the expression of HIF-α and VEGF hence blocking angiogenesis in the 
synovial tissues of CIA mice [40]. As a result, synovial inflammation was less severe in 
FK-228-treated mice [40]. 
 
Although the anti-angiogenic effects of HDAC inhibitors had been well 
documented in various pre-clinical models, their impact on angiogenesis have never been 
assessed in RA models. Hence, it was of interest to investigate anti-angiogenic activities 
of HDAC inhibitors in RA-related models. Anti-angiogenesis alone may not suffice for 
RA management as it occurs mainly in the early stages of the disease. However, 
angiogenesis inhibition can serve as adjuvant therapy. The anti-angiogenic effects of 
HDAC inhibitors are summarized in figure 1.10.  





Figure 1.10 Anti-angiogenic effects of HDAC inhibitors 
 
In addition, p38 activation is involved in endothelial activities like chemotaxis 
and vasodilatation [108]. Chemotaxis is an event whereby inflammatory cells migrate 
from the bloodstream to the inflamed synovium to propagate pre-existing inflammation 
in the RA joint [119]. Chemokines are proteins that are involved in leukocyte migration 
through the endothelium into the inflamed synovium [120]. Subsequently, localization of 
leukocytes in inflamed tissues is often due to the action of chemotactic substances which 
cause them to migrate from blood vessels to affected areas [120]. During inflammatory 
reactions such as acute respiratory distress syndrome, sepsis, ischemia and reperfusion, 
leukocytes (lymphocytes, monocytes and neutrophils) are rapidly mobilized from the 
bone marrow [120]. It is thought that this mobilization is stimulated by systemic acting 
factors that are generated at the site of inflammation [120]. The CC and CXC chemokines 










responses [120]. In addition, increased blood levels of CC and CXC chemokines have 
been reported in clinical diseases [120].  
 
In RA, polymorphonuclear leukocytes (PMNs) are thought to play an important 
role and large numbers tend to accumulate in the synovial fluid of affected joints [120]. 
Hollander et al proposed that PMNs can be attracted to affected joints towards a 
rheumatoid factor or complement via chemotaxis [120]. Chemokines like granulocyte 
chemotactic protein (GCP-2), MCP-2, macrophage migration inhibitory factor (MIF) and 
IL-8 were found to be elevated in the sera, synovial fluid and tissues of RA patients [120]. 
Their production could be stimulated by IL-1 and TNF-α [114, 120]. There had not been 
studies that observe the effects of HDAC inhibitors on chemokine production. Since 
HDAC inhibitors are able to suppress pro-inflammatory cytokines released from 
monocytes, it was of interest to determine if they can also suppress chemokines released 
from monocytes. 
 
In addition, p38 can also regulate adhesion molecules like E-selectin and VCAM-
1 on endothelial cells [119]. The aforementioned molecules are required for the 
movement of leukocytes on the endothelium before migrating to the inflammatory site 
[105, 106]. Moreover, p38 regulates monocyte chemotactic protein (MCP)-1 chemokine 
[121].  p38 may also regulate vasodilatation as iNOS is a key target of this kinase [95]. 
iNOS is needed to regulate NO production in order to induce vasodilatation to increase 
the blood flow, nutrients and oxygen transported to the inflamed tissues [91]. 




Vasodilatation then facilitates the trafficking of leukocytes to such site(s) [91]. In 
summary, MAPKs have significant roles to play in RA pathogenesis. Therefore, HDAC 
inhibitors may suppress the p38 MARK signaling pathway and subsequently inhibit 
downstream inflammatory effectors.. However, the suppressive effects of HDAC 
inhibitors on p38 MAPK signaling pathway have not been attempted.  
 
In summary of available literature, HDAC inhibitors exhibited promising anti-
inflammatory and anti-rheumatic activities in rodent AIA, AMA and CIA models as well 
as in human primary cultures and tissue biopsy explants. However, the mechanisms of 
action of HDAC inhibitors have not been well elucidated. 




It is widely accepted that epigenetics has a role to play in cancer pathogenesis 
[122]. Gene expression is partly regulated by the differential acetylation of histones 
[11-13].  As depicted in Figure 1.3, this phenomenon is mediated by a balance in 
HAT and HDAC activities [11-13]. Increased histone acetylation is associated with 
transcriptional activation while hypoacetylated histones are associated with 
transcriptionally inactive chromatin [11-13]. The acetylation status may therefore 
control a variety of cellular processes including cell proliferation, signaling, 
regulation of transcription and apoptosis [123].  
 
As a result, a number of compounds that inhibit HDACs had been identified 
[11-13]. They were observed to induce growth arrest, differentiation and apoptosis 
[12-14]. Furthermore, these HDAC inhibitors could demonstrate selective toxicity in 
cancer cell lines [124, 125]. They have since entered clinical trials for oncology 
indications (Table 1.2). Besides being anti-neoplastic, HDAC inhibitors also 
displayed potent anti-inflammatory and anti-rheumatic effects in animal models [20, 
21, 24, 39-42, 55]. However, the mechanisms of action of HDAC inhibitors have not 
been well elucidated. Herein, the anti-inflammatory and anti-rheumatic activities of 
HDAC inhibitors were planned to be observed in various in vitro setups. Several anti-
inflammatory and anti-rheumatic mechanisms of action of the HDAC inhibitors with 
relevance to RA were proposed. The potential anti-inflammatory and anti-rheumatic 








Figure 2.1 Possible anti-inflammatory and anti-rheumatic mechanisms of HDAC inhibitors 
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It is hypothesized that HDAC inhibitors exhibit their potent anti-
inflammatory and anti-rheumatic activities by: 
1. Inhibiting the proliferation of RASFs by inducing or up-regulating CDK 
inhibitors 
2. Inhibiting the NF-κB and MAPK signaling pathway 
3. Inhibiting the downstream effectors of NF-κB and/ or MAPK signaling 
pathways such as pro-inflammatory cytokine, NO, VEGF, chemokine and 
MMP secretion 
4. Modulating gene expression 
 
Hence, the objectives of the PhD project were to investigate the effects of 
HDAC inhibitors on: 
1. The inhibition of RASF-like cell proliferation 
2. The influence on gene expression 
3. The inhibition of the NF-κB and MAPK signaling pathways 
4. The inhibition of pro-inflammatory cytokine and NO secretion in RASF-
like and monocyte-like cells 
5. The inhibition of other downstream effectors of the NF-κB and MAPK 
signaling pathways such as angiogenesis, chemotaxis and bone and 
cartilage damage 
 
CHAPTER THREE – EFFECTS OF HDAC INHIBITORS 




3.1 Materials and Methods 
3.1.1 Materials 
A. Cell Line and Cell Culture Medium 
E11 is a human RASF cell line established from the knee joint tissues of a RA 
patient [129]. It was kindly provided by Prof. Y. Tanaka (University of Occupational 
and Environmental Health, Kitakyushu, Japan). Cells were maintained in Roswell 
Park Memorial Institute (RPMI) 1640 medium (Invitrogen, Carlsbad, CA 92008, 
USA) supplemented with 10% FBS (HyClone, Logan, UT 84321, USA), 1% 
antibiotic antimycotic solution (Invitrogen, USA) and incubated at 37
o
C with 5% 
carbon dioxide (CO2).  
 
B. HDAC Inhibitors and Methotrexate (MTX)  
MS-275 (Axxora, Cambridge, CB4 0WS, UK), SAHA (Toronto Research 
Chemicals Inc., North York, M3J 2J8, Canada), PXD-101 and TSA (Cayman 
Chemicals, Ann Arbor, Michigan 48108, USA) as well as MTX (Sigma Aldrich, St. 
Louis, MO 63103, USA) were purchased.  
 
C. Cell Proliferation Assay 
Dimethylthiazol tetrazolium bromide (MTT) and dimethyl sulphoxide (DMSO) 
were purchased from Sigma Aldrich, USA.  
 
D. Cytotoxicity Assay 
Tryphan blue powder was from Sigma Aldrich, USA. A lactate dehydrogenase 
(LDH) cytotoxicity detection kit (Roche, Florence, SC 29506, USA) was purchased. 
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E. Flow Cytometry Analysis 
Propidium iodide (PI) and ribonuclease were purchased from Sigma Aldrich, 
USA.  Absolute ethanol 99% (w/w) was from Fisher Scientific, Singapore.  
 
F. Western Blot Analysis  
Ammonium persulphate (APS), 30% Acrylamide/ Bis (29:1), bromophenol 
blue, dithiothretitol (DTT) and polyvinylidene fluoride (PVDF) membranes were 
from Bio-Rad, Hercules, CA 94547, USA. Bovine serum albumin (BSA) was from 
Amresco Inc., Solon, OH 44139-0098, USA. Glycerol and glycine was from 
Biological Industries Ltd, Kibbutz Brit Haemek 25115, Israel. 
Tetramethylethylenediamine (TEMED) was from Sigma Aldrich, USA. Methanol was 
from Fisher Scientific, Singapore. Sodium chloride (NaCl) was from LabScan, 
Gliwice 44-100, Poland. Proteinase inhibitor cocktail tablets were from Roche, USA. 
10% sodium dodecyl sulphate (SDS) was from National University Medical Institute, 
Singapore. Tris buffers pH 7.4 and 8.0 were from 1
st
 Base, Singapore. Primary 
antibodies against p16 (C20), p21 (187), p27 (C20) and β-actin were purchased from 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA 95060, USA. Secondary antibodies 
which were either peroxidase conjugated ImmunoPure goat anti-mouse or goat anti-
rabbit immunoglobulin (IgG) and SuperSignal West Pico Chemiluminescent Substrate 
were purchased from Pierce Biotechnology, Rockford, IL 61105, USA.  
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A. Cell Proliferation Assay 
E11 cells were seeded in 24-well plates and incubated for 24 hr before varying 
concentrations of HDAC inhibitors or MTX (final concentration 2.5 nM – 25 µM) 
were added and incubated for another 72 hr. Formazan formed was solubilized by 
DMSO and levels were determined by measuring optical densities with Genios plate 
reader (Tecan, Männedorf, Switzerland) at 570 nm. Cell proliferation was expressed 
as percentage cell growth with respect to control cells. From which, the percentage 
inhibition of cell proliferation could be calculated. 
 
B. Cytotoxicity Assay 
In an initial study, E11 cell viability was assessed by tryphan blue exclusion 
method after 72 hr incubation with HDAC inhibitors or MTX at two concentrations.  
A low concentration of 50 nM and a high concentration of 5 µM were chosen based 
on the IC50 values obtained from earlier proliferation studies. In later studies, the 
cytotoxicity of HDAC inhibitors and MTX were further investigated using a Cyto-
toxicity Detection Kit (Roche, USA), which is dependent on LDH released from the 
cytosol of dead cells into the media. Briefly, E11 cells were maintained in RPMI 1640 
supplemented with 1% FBS, 1% antibiotic-antimycotic solution and incubated at 
37
o
C with 5% CO2 prior to seeding in 96-well plates. These were incubated for 
another 24 hr before varying concentrations of HDAC inhibitors or MTX (final drug 
concentration 2.5 nM – 25 µM) were added. The medium was aspirated after 72 hr 
and retained for cytotoxicity analyses, performed in accordance to manufacturer 
instructions. Optical densities were read with Genios plate reader at 490 nm with a 
reference wavelength of 620 nm. The optical density reading obtained is directly 
CHAPTER THREE – EFFECTS OF HDAC INHIBITORS 




proportional to the amount of LDH released from the cytosol of dead cells into the 
media. 
 
C. Interaction between HDAC Inhibitors and MTX 
Since HDAC inhibitors proved to be effective in RASF proliferation inhibition, 
it was of interest to investigate if interaction exists between HDAC inhibitors and 
MTX when used in combination. MTX was chosen as it is the gold standard DMARD 
used in RA. The median-drug effect analysis method by Chou and Talalay [130] has 
been widely used for the evaluation of potential interaction between different agents. 
Drug interaction is assessed by calculating the combination index (CI) at a series of 
values of fraction of the cells affected (fa).  
 
Hence, E11 cells were seeded in 24-well plates and incubated for 24 hr. The 
medium was aspirated and replaced with a combination of HDAC inhibitors and 
MTX in a fixed IC50-based molar concentration ratio. A HDAC inhibitor: MTX ratio 
of 5: 3 was chosen based on the anti-proliferative IC50 values obtained earlier. MTT 
assay was again performed. Cell proliferation was expressed as percentage cell 
growth with respect to control cells. From which, the percentage inhibition of cell 
proliferation could be calculated. 
 
For agents that are mutually non-exclusive i.e. they possess different 
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CI = (D)1/(Dx)1 + (D)2/(Dx)2 + (D)1(D)2/(Dx)1(Dx)2 
whereby (D)1 and (D)2 are doses of Drug 1 and Drug 2 in combination that 
inhibit x% of cell proliferation and (Dx)1 and (Dx)2 are the doses of Drug 1 
and Drug 2 alone that also inhibits x% of cell proliferation 
CI < 1 indicates synergism 
CI = 1 indicates an additive relationship 
CI > 1 indicates antagonism 
 
By repeating the calculations at various effect levels, a median-drug-effect plot 
can be constructed by plotting CI versus fa. 
 
D. Flow Cytometry Analysis 
E11 cells were seeded in 25mm
3
 culture flasks and incubated for 24 hr before 
varying concentrations of HDAC inhibitors (final concentration 1 nM – 50 µM) were 
added and incubated overnight. The cells were trypsinized and washed before fixing 
in ice-cold 70% (w/w) ethanol overnight. Prior to analyses, cell suspensions were 
washed and re-suspended in a staining buffer containing 50 µg/ml of PI and 70 units 
of RNase. Then, they were incubated for at least 1 hr in the dark at room temperature. 
Cell cycle distribution was visualized using Coulter Elite flow cytometer (Beckman 
Coulter, Inc., Fullerton, CA 92834, USA). Histograms were analyzed with Summit 
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E. Western Blot Analysis for p16, p21 and p27 Proteins 
E11 cells were seeded in 6 cm cell culture dishes and incubated for 24 hr 
before HDAC inhibitors (final concentration 50 nM) were added. Samples were 
harvested at stipulated intervals. Proteins were separated by 12.5% sodium dodecyl 
sulfate–polyacrylamide gel (SDS–PAGE) and transferred to PVDF membrane which 
was probed with primary antibodies against p16, p21, p27 and β-actin followed by 
secondary antibodies. SuperSignal West Pico Chemiluminescent Substrate was added 
and bands were visualized by MultImage Light Cabinet (Alpha Innotech, San Leandro, 
CA 94577, USA).  
 
F. Calculations 
50% inhibitory concentration (IC50) values were calculated using GraphPad 
Prism 5 Software (GraphPad Software Inc., San Diego, CA, USA). P values less than 
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A. HDAC Inhibitors Induced Growth Arrest of E11 RASF-like Cells in a 
Concentration-Dependent but Non-Cytotoxic Manner 
In order to determine if HDAC inhibitors affected cell proliferation, MTT 
assays were performed. MTX, the first line DMARD for RA, was used as a positive 
control. HDAC inhibitors and MTX seemed to possess similar potencies and inhibited 
E11 proliferation in a concentration-dependent manner (Figure 3.1 and Table 3.1). 
Interestingly, the effective levels of HDAC inhibitors to suppress E11 cell 
proliferation were fairly low and their IC50 values were less than 100 nM (Table 3.1).  
 
CHAPTER THREE – EFFECTS OF HDAC INHIBITORS 










CHAPTER THREE – EFFECTS OF HDAC INHIBITORS 




Table 3.1 IC50 values of HDAC inhibitors and MTX on E11 cell proliferation 
inhibition. 95% confidence intervals are listed within the parentheses.  
 
 HDAC inhibitors MTX 
 MS-275 PXD-101 SAHA TSA  
 
IC50 values (nM) 
 
65 
(55 – 81) 
 
30 
(25 – 36) 
 
44 
(41 – 61) 
 
52 
(47 – 62) 
 
33 
(29 – 40) 
 
In order to rule out cytotoxcity in the anti-proliferative results, E11 cells that 
were treated with HDAC inhibitors and MTX were examined by tryphan blue 
exclusion under the microscope. Incubation of E11 cells with a high concentration of 
HDAC inhibitors at 5 µM for 72 hr did not cause significant cell death (cell viability > 
95%). However, MTX resulted in significant E11 cell cytotoxicity. At 50 nM and 5 
µM, cell viability was 80% and 40%, respectively.  
 
As counting of cells under a microscope in tryphan blue exclusion may be 
subjective, we confirmed our results with LDH assays. HDAC inhibitors did not 
increase LDH release into cell culture media compared to control, even at 25 µM 
(Figure 3.2). On the contrary, MTX displayed concentration-dependent cytotoxicity. It 
elevated LDH activity significantly (p < 0.01) even at 10 nM. Therefore, the anti-
proliferative activity of MTX was associated with cytotoxicity while that of HDAC 
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- : low control where cells were maintained in growth medium only. This 
provided information about the LDH activity released from normal cells or 
spontaneous LDH release 
 
+: high control where cells were treated with Triton-X-100 solution (final 
concentration 1%). This provided information about the maximum releasable 
LDH activity in the cells or maximum LDH release 
 
 
** P < 0.01 versus low control, *** P < 0.001 versus low control, by two-tailed 
unpaired t-test
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B. Combination of HDAC Inhibitors with MTX can be Synergistic for E11 
Growth Arrest 
Since HDAC inhibitors showed comparable potencies with MTX, it was of 
interest to determine the interaction between HDAC inhibitor and MTX when used in 
combination. Median effect analysis over a range of HDAC inhibitor and MTX 
concentrations, administered at fixed IC50 ratio of 5:3, yielded CI values less than 1, 
for the combination of MS-275 or TSA with MTX. This denoted synergistic 
interaction between MS-275 or TSA with MTX (Figure 3.3 and Table 3.2). CI values 
exceeded 1 when fa exceeded 0.7 for the combinations of PXD-101 or SAHA with 
MTX, implying antagonistic interaction between PXD-101 or SAHA with MTX at 
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Figure 3.3 Median-drug-effect plots for combinations of HDAC inhibitors with MTX 
 
 
Table 3.2 Combination indices for the drug combinations in E11 cells 
 


















0.2 0.00392 < 0.001 < 0.001 0.197 
0.3 0.00527 0.00321 0.00356 0.0686 
0.4 0.00676 0.0123 0.0135 0.0319 
0.5 0.00856 0.0420 0.455 0.0192 
0.6 0.0109 0.143 0.154 0.0154 
0.7 0.0142 0.550 0.583 0.0162 
0.8 0.0197 2.82 2.95 0.0213 
0.9 0.0326 33.1 34.0 0.0363 
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C. HDAC Inhibitors caused E11 Growth Arrest by Inducing Cell Cycle Arrest 
Since the anti-proliferative effects of HDAC inhibitors were not due to 
cytoxicity, cell cycle phase changes were suspected. The impact of HDAC inhibitors 
on cell cycle distribution was then investigated. HDAC inhibitor treatment over the 
tested range did not significantly increase the sub G1 peak, confirming that they did 
not cause apoptosis (Figure 3.4). All the tested HDAC inhibitors induced G0/G1 phase 
arrest in E11 cells, even at concentrations as low as 1 nM. The results were in line 
with previous studies albeit in different cell lines [20, 131]. After 24 hr incubation 
with 1 nM of MS-275, PXD-101, SAHA or TSA, G0/G1 fraction was increased from 
49.7 ± 0.7% to 79.9 ± 3.3% (p < 0.001, n = 5), 56.1 ± 0.4% to 75.1 ± 1.2  (p < 0.001, 
n = 5), 49.1 ± 1.6% to 68.8 ± 0.2% (p < 0.001, n = 5), 50.4 ± 0.2% to 73.6 ± 0.3% (p 
< 0.001, n = 5), respectively (Table 3.3). Phase arrest appeared to be concentration-
independent as further increases in HDAC inhibitor concentrations did not alter the 
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Figure 3.4 A representative DNA histogram and HDAC inhibitors induced G0/G1 




 *** P < 0.001 versus vehicle control, by two-tailed unpaired t-test 
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Table 3.3 Changes in G0/G1 fraction in HDAC inhibitor-treated E11 cells 
 
Control versus  
HDAC Inhibitor Treatment (1 nM) 






49.7 ± 0.7  




56.1 ± 0.4 




49.1 ± 1.6 




50.4 ± 0.2 
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D. HDAC Inhibitors Up-Regulated p21 Expression 
As HDAC inhibitors induced cell cycle arrest at G0/G1 phase, it was of interest 
to determine if the aforementioned observation was attributable to their impact on 
CDK inhibitors, such as p16, p21 and p27, which play important roles in cell cycle 
control. Moreover, it had been demonstrated that HDAC inhibitors could up-regulate 
the expression of these proteins and this can be one of the common anti-cancer 
mechanisms of HDAC inhibitors [12, 13]. To assess the impact of HDAC inhibitors 
on p16, p21 and p27 expression, E11 cells were incubated with 50 nM of HDAC 
inhibitors (a concentration close to their anti-proliferative IC50 value) for up to 24 hr. 
Expression of p16, p21 and p27 were then monitored by western blot. It was found 
that E11 cells expressed p16 and p27 endogenously but not p21. HDAC inhibitors did 
not have a significant impact on p16 and p27 expression (results not shown). However, 
HDAC inhibitors induced p21 expression after 24 hr incubation (Figure 3.5). The 
results were consistent with previous studies whereby p21 expression increased with 
HDAC inhibitor exposure [54, 55].  
 




 MS-275                    PXD101                        SAHA                           TSA    
    0 h     2 h       8 h       24 h     2 h      8 h       24 h      2 h       8 h       24 h    2 h       8 h       24 h  
p21 
-actin 
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In RA, excessive synovial cell proliferation leads to the formation of the panus 
[1-3]. Hence, the inhibition of synovial cell proliferation may slow down or halt 
disease progression [11]. Since synovial fibroblasts play important roles in RA 
pathogenesis and work actively to drive joint destruction, we investigated the anti-
rheumatic activities of HDAC inhibitors in E11 cells, a cell line developed from 
RASFs [129].  
 
HDAC inhibitors were found to inhibit E11 proliferation in a concentration-
dependent manner, with IC50 values comparable to that of MTX. Therefore, it could 
be concluded that HDAC inhibitors can inhibit RASF proliferation as effectively as 
MTX. IC50 values of HDAC inhibitors on RASF proliferation were noted to be about 
50 nM while the effective concentrations of HDAC inhibitors in cancer cells were 
usually observed to be in the micromolar range [12, 13]. Hence, it may be postulated 
that HDAC inhibitor concentrations needed for anti-inflammation may be lower than 
that required for anti-neoplasm as the mechanisms of actions may differ. Lower doses 
will be advantageous as there can be less dose-dependent side effects when HDAC 
inhibitors are used for anti-inflammatory purposes.  
 
Combination of HDAC inhibitors with DMARDs may be advantageous for 
RA management. This is because conventional RA treatment with a single DMARD 
usually fails to control symptoms or disease progression adequately [4]. It had been 
shown that combination achieved better results than mono-therapy and toxicities were 
not accelerated [4, 10]. Combination of drugs may lead to synergistic effects. 
Otherwise, additive results will also be beneficial for RA if the combination can halt 
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disease progression. Thus far, combining HDAC inhibitors with anti-cancer drugs 
often lead to optimistic results [132]. In current clinical trials, combination of AN-9, 
CI-994, MS-275, PB, PXD-101, SAHA and VPA with various chemotherapeutic 
agents are investigated [132]. As the anti-rheumatic mechanisms of HDAC inhibitors 
appear to be rather different from established DMARDs, combining HDAC inhibitors 
with DMARDs may be synergistic or at least additive. Since MTX is the gold 
standard DMARD for RA management, it was a rational candidate to choose for 
combination with the HDAC inhibitors in this study. It was found that combination of 
some HDAC inhibitors (MS-275 and TSA) with MTX can be synergistic in inhibiting 
E11 cell proliferation. Since the interaction between HDAC inhibitor and MTX is 
synergistic, lower doses of HDAC inhibitors and MTX can be used when they are in 
combination. This can minimize potential dose-dependent side effects. 
 
In addition, HDAC inhibitors inhibited RASF proliferation in a concentration-
dependent manner without causing cytoxicity. This was confirmed via tryphan blue 
exclusion, LDH cytotoxicity assay and flow cytometry. More than 90% of the cells 
were not dead even at high micromolar concentrations as shown by flow cytometry. 
The results were consistent with previous studies [54, 55].  
 
It was of interest to determine if the proliferation inhibition observed was due 
to cell cycle changes. Indeed, HDAC inhibitors induced G0/G1 phase arrest. However, 
phase arrest was not concentration-dependent. It might appear contradictory to the 
concentration-dependent effects of HDAC inhibitors on RASF proliferation but this 
might be explained that HDAC inhibitors exerted effects on the cell cycle via an ‘on-
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off’ mechanism ie. when cells were exposed to above a threshold concentration of 
HDAC inhibitors, phase arrest occurs.  
  
RA is associated with synovial hyperplasia and panus formation [1, 2]. The 
hypertrophic and invasive nature of RASFs could be due to impaired activities of 
CDK inhibitors p16, p21 and p27. It was found that HDAC inhibitors up-regulated 
p21 expression in E11 RASF-like cells. Moreover, it was observed that p21 up-
regulation was associated with G0/G1 phase arrest which is in line with previous 
studies [54, 55]. Therefore, modulating p21 may be practical for RA management. 
Gathering from the cell proliferation studies, flow cytometry and western blot 
analyses, HDAC inhibitors could have inhibited RASF proliferation by inducing cell 
cycle arrest, through the induction of p21 expression. 
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4.1 Materials and Methods 
4.1.1 Materials 
A. Cell Line and Cell Culture 
E11 cells were maintained in culture conditions as stated on page 50 of 
Chapter Three.  
 
B. RNA Extraction 


















CHAPTER FOUR – GENE PROFILING AFTER 





A. RNA Extraction and Quality Assessment 
 E11 cells were seeded in 6 cm culture dishes and incubated for 24 hr before 
HDAC inhibitors (final concentration 100 nM) were added. After 1 hr, LPS (final 
concentration 5 μg/ml) was added and incubated for 24 hr before RNA extraction was 
carried out. Three independent batches (Batch X, X1 and X2) of RNA samples 
representing three biological replicates for each experimental condition were 
processed. Total RNA from 15 samples representing five different experimental 
conditions was extracted using RNeasy mini kit. Optical density for each sample of 
RNA was measured at 260 and 280 nM using NanoDrop ND-1000 (NanoDrop 
Technologies, USA). All RNA samples isolated had OD 260/280 ratio > 1.8 to ensure 
that the samples were free from protein contamination. All RNA samples isolated also 
had OD 260/230 ratio > 1.8 to ensure that the samples were free from organic 
component or salt contamination. Each isolated RNA sample was subjected to further 
quality checks to ensure the integrity of the RNA with Agilent RNA 6000 Nano 
LabChip using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, 
USA). All RNA samples were verified to be intact with distinct 28S and 18S bands at 
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B. Microarray Hybridization and Image Acquisition 
 The service was provided by Genomax, Singapore. For each sample, RNA 
was synthesized using Agilent Quick Amp Labeling Kit (Agilent Techonlogies, USA). 
It consists of a two step labeling protocol which converts mRNA primed with an oligo 
(d)T-T7 primer into double stranded DNA with moloney murine leukemia virus-
reverse transcriptase followed by amplifying samples using T7 RNA polymerase, 
resulting in labeled anti-sense cRNA. Briefly, 5 µg of total RNA was primed for first 
strand cDNA synthesis using T7 oligo (d)T-T7 primer provided, followed by second 
strand cDNA synthesis. The cDNA formed was purified and transcribed in vitro using 
5-(3-aminoallyl)-2’uridine-5’-triphosphate (aminoallyl-UTP) nucleotide to obtain 
UTP labeled RNA. The UTP labeled RNA synthesized was subsequently purified and 
25 µg of it was coupled to cyanine (Cy)5 fluorescent dye from Amersham 
Biosciences (Piscataway, NJ, USA). Absorbance of Cy5 labeled RNA was measured 
using NanoDrop ND-1000 to ensure adequate Cy5 labeling efficiency. All Cy5 
labeled RNA samples were verified to have adequate labeling efficiency. They were 
fragmented and 10 µg of Cy5 labeled aRNA for each sample was hybridized to each 
of the 60 mer oligonucleotide microarray (Agilent Technologies). The array is made 
up of 41000 human genome probes and 78 experimental probes. Each oligonucleotide 
probe is designed to hybridize to a specific target gene described in the current public 
domain contents such as UniGene, Cancer Genome Anatomy Project, BioCarta, 
Kyoto Encyclopedia of Genes and Genomes and validated by the Human Genome 
Sequencing Project. Triplicate arrays were performed for each individual RNA 
sample. Following hybridization, arrays were washed, dried and scanned using a dual-
laser DNA Microarray Scanner with SureScan technology (Agilent Technologies). 
Images for Cy5 fluorescence were acquired. 
CHAPTER FOUR – GENE PROFILING AFTER 




C. Microarray Data Mining 
The service was provided by Genomax, Singapore. Fluorescence data was 
extracted using Genepix Pro 4.1 (Molecular Devices Corporation, Sunnyvale, CA, 
USA). Following extraction, data from each chip was first normalized by quantile 
normalization [179] to compensate for systematic technical differences between the 
chips using the Matlab software (MathWorks, Natick, MA, USA). It was then filtered 
to remove signals flagged absent by the scanner. The normalized data were further 
subjected to per gene normalization to the median value for each gene within each 
sample using the Genespring software (Silicon Genetics, Redwood, CA, USA). 
Subsequently, the mean normalized gene intensity for each sample was obtained by 
averaging the normalized gene intensity. Using Welch One Way ANOVA (p value < 
0.05), genes that were statistically different between control and HDAC inhibitor-
treated samples were identified. The p value obtained was corrected using Benjamini-
Horchberg false discovery rate multiple testing correction at a false discovery rate of 
5% [180]. The group of genes identified was further filtered for at least 2-fold 
differential regulation. Genes common to batches of RNA after filtering on fold 
change were further subjected to hierarchical clustering. Gene functional analysis was 
subsequently performed using Genespring® and Genecards® (Crown Human 
Genome Center and Weizmann Institute of Science, Israel). 
 
D. Pathway Analysis of Differentially Expressed Genes in E11 cells 
 Entrez Gene accession numbers of differentially expressed genes in E11 cells 
were entered into Pathway Studio software (Adriane Genomics Inc., Rockville, MD, 
USA) which is a web-based database consisting of a myriad of individually modeled 
relationships between proteins, genes, complexes, cells, tissues, drugs and diseases 
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[180]. The data input was queried against the Pathway Studio knowledge base for 
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4.2 Results  
A. HDAC Inhibitors Induced Gene Expression Changes in E11 RASF-like Cells 
 In order to identify genes that were differentially expressed between control 
and HDAC inhibitor-treated cells, microarray experiments were carried out. After 
initial quantile normalization and flagging out probes without signal, a total of 17754 
probes were identified. Each probe was further normalized to its median intensity 
value (Figure 4.1). The aforementioned is a useful normalization process that allows 
for the comparison of gene expression profiles and subsequent clustering of genes that 
may be expressed at different levels. From figure 4.1, the normalized intensities of all 
fifteen replicate samples gather around the value of zero on the plot so as to ensure 
















M, MS-275; P, PXD-101; S, SAHA; T, TSA [R and TMS are not assessed in this thesis]
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 After normalization to the median intensity value of each probe, statistical 
analyses were performed to identify probes with intensity values that were statistically 
different between control and HDAC inhibitor-treated samples. The identified probes 
were then filtered based on a two-fold differential expression. In batches X, X1 and 
X2, 7939, 7909 and 5189 probes were identified, respectively. Among the 
differentially regulated genes, 44 probes representing 34 genes were found to be 
commonly present in both batches of RNA samples (Figure 4.2). 
 
The visualization of grouping of the common probes based on their expression 
profile was obtained using hierarchical clustering. Gathering from the clustering data 
(Figure 4.3), it was observed that the expression patterns for similar experimental 
conditions were similar between the batches of RNA. 
 
In order to further understand the biological significance of the common 
probes, the genes represented by these probes that were significantly differentially 
regulated based on ANOVA with at least 2-fold difference in the gene expression 
values between control and HDAC inhibitor-treated samples were determined. About 
34 genes out of 44 probes analyzed were identified to be differentially regulated when 
compared to control (Table 4.1). 3 genes were up-regulated while 31 genes were 
down-regulated. Among the up-regulated genes were those involved in cell cycle 
arrest, NF-κB inhibition and anti-inflammatory cytokine production while among the 
down-regulated genes were those involved in cell cycle progression, NF-κB and 
MAPK activation, pro-inflammatory cytokine, chemokine and MMP secretion as well 
as angiogenesis.  
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Figure 4.2 Number of significantly and differentially regulated probes between 

























Figure 4.3 Hierarchical clustering analysis of the differentially expressed probes common to all three batches of RNA samples 
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Table 4.1 Differentially regulated genes after HDAC inhibitor treatment 
Probe name Gene symbol Average 
fold change#  
Summary of function 
A_23_P315364 
 
CXCL2 -5.303 Chemokine 
A_23_P205646 
 
MAPK5* -2.25 MAPK signaling 
A_24_P124550 
 
Cyclin D1 -9.153 Cell cycle progression 
A_23_P203173 
 
IL10RA* 10.445 Anti-inflammatory cytokine 
A_23_P218918 
 
FGF2* -13.125 Pro-angiogenic factor 
A_23_P104798 
 
IL-18* -2.578 Pro-inflammatory cytokine 
A_23_P216812 
 





-2.848 Pro-angiogenic factor 
A_23_P62276 
 
NKAP -2.295 NF-κB signaling 
A_23_P81805 
 
VEGFA -2.213 Pro-angiogenic factor 
A_23_P102000 
 
CXCR4 -3.12 Chemokine 
A_23_P102000 
 
MIF -2.163 Chemokine 
A_24_P251764 
 
CXCL3 -4.88 Chemokine 
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Table 4.1 Differentially regulated genes after HDAC inhibitor treatment - continued 
Probe name Gene symbol Average fold 
change# 
Summary of function 
A_23_P37910 
 
MAPK3* -2.145 MAPK signaling 
A_23_P131676 
 















-2.295 Toll-like receptor signaling 
A_23_P256223 
 
VBP1 -2.075 Pro-angiogenic factor 
A_24_P379413 
 










-2.408 NF-κB signaling 
A_24_P334300 
 
FGF12 -3.395 Pro-angiogenic factor 
A_24_P73669 
 
GSPT1 -2.18 Cell cycle progression 
A_23_P38505 
 
CXCL16 -2.315 Chemokine 
A_24_P916195 
 
GTSE1 -2.18 Cell cycle progression 
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Table 4.1 Differentially regulated genes after HDAC inhibitor treatment - continued 
Probe name Gene symbol Average fold 
change# 
Summary of function 
A_23_P256312 
 
MST1R -2.728 Pro-inflammatory cytokine 
A_23_P397856 
 
TIRAP -2.338 Pro-inflammatory cytokine 
A_23_P29347 
 
MAPK12 -3.53 MAPK signaling 
A_32_P89837 
 
TRAF3 -2.515 Pro-inflammatory cytokine 
A_23_P203888 
 
MMP19 -2.068 ECM breakdown 
A_23_P168651 
 
CDK6 -2.535 Cell cycle progression 
A_23_P169331 
 
TRAF2 -2.348 Pro-inflammatory cytokine 
A_23_P126844 
 
TNFRSF25* -2.943 Pro-inflammatory cytokine 
 
 
# Average fold change represents the mean fold change value obtained from 
averaging the fold changes for Batch X, X1 and X2. 
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B. Network and Pathway Analysis of Differentially Expressed Genes 
 The presence of any functional relationships and potential interactions of the 
genes identified to show at least two-fold differential regulation between control and 
HDAC inhibitor-treated cells was further explored using Pathway Studio (Adriane 
Genomics Inc.). Genes were mapped to a genetic network (Figures 4.4 – 4.7) as 
defined by the Pathway Studio tool. From this network, a unique molecular signature 
of gene interaction involved in a range of inflammation-related processes can be 
observed. They include genes involved in apoptosis, cell growth and differentiation, 
cell cycle arrest, MAPK, NF-κB, STAT and TNFR-AP1 signaling pathways as well 


















Figure 4.4 Genetic network of differentially expressed genes involved in apoptosis, cell growth and differentiation as well as cell cycle arrest 
between control and HDAC inhibitor-treated cells  
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Figure 4.5 Genetic network of differentially expressed genes involved in STAT 
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Figure 4.6 Genetic network of differentially expressed genes involved in TNFR-AP-1 









CHAPTER FOUR – GENE PROFILING AFTER 




Figure 4.7 Genetic network of differentially expressed genes involved in NF-κB 
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 There had been several studies which probed the gene expression profiles of a 
single HDAC inhibitor, usually in a single cell line [133, 134]. Herein, a 
comprehensive analysis of the genes that characterized the response of E11 cells to 
the treatment of multiple HDAC inhibitors like MS-275, PXD-101, SAHA and TSA, 
was investigated using microarray technology. It was observed that the HDAC 
inhibitors affected several genes. However, MS-275 seemed to generate an expression 
profile that is different from the other HDAC inhibitors in previous studies [126]. 
Keith et al had previously suggested that differences occurred as a result of differing 
potency against nuclear HDAC enzymes [126]. Herein, fewer genes were affected by 
MS-275 as compared to the other HDAC inhibitors. Surprisingly, these differences 
did not manifest at cellular levels. In fact, MS-275 is often more potent than the other 
tested HDAC inhibitors in our subsequent observations. 
 
 Even with the differences seen with MS-275 in previous studies [126], the 
tested HDAC inhibitors still regulated a common set of 44 probes representing 34 
genes. The 34 genes were significantly and differentially regulated based on ANOVA 
with at least two-fold difference in the gene expression values between control and 
HDAC inhibitor-treated samples. In addition, the total number of commonly regulated 
genes coincides with 1 – 2% of the total number of genes regulated by HDAC 
inhibitors reported in literature [126]. In this common gene set, there are genes which 
are involved on cell proliferation, cell cycle progression and arrest, NF-κB and 
MAPK signaling, pro- and anti-inflammatory cytokine secretion, chemokine secretion 
as well as angiogenesis. Hence, these genes would be expected to be regulated in cells.  
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As observed in previous studies, CDK inhibitors like p21 is markedly up-
regulated by HDAC inhibitors in many cell types, at both mRNA and protein levels 
[14, 55, 56, 135, 136]. p21 is a common gene regulated by NaB and TSA in most 
gene microarray studies, usually 2 – 5-fold depending on the cell line and exposure 
time [127, 133, 134].  
 
 The anti-rheumatic mechanisms of HDAC inhibitors could also be mediated 
through the inhibition of the NF-κB pathway [137]. NF-κB is a pivotal regulator of 
inflammation in RA [136]. NF-κB is activated in synovial tissues in the early stages 
of inflammation as well as in the late stages of RA [137]. As activation of NF-κB in 
synovial fibroblasts profoundly enhances proliferation, motility and matrix-degrading 
activity, an essential role for NF-κB had been proposed in the tumor-like behavior of 
RASFs [137]. Microarray data revealed that HDAC inhibitors might influence NF-κB 
signaling. Many pro-inflammatory cytokines that are involved in RA such as COX-2, 
iNOS, IL-1β, IL-6, TNF-α, VEGF and MMPs are up-regulated after NF-κB activation 
[137]. Beside the NF-κB signaling pathway, the MAPK signaling network is an 
attractive therapeutic target as it is one of the major effector limbs in inflammation 
[67-70]. The MAPK pathway is important TLR signaling, through which pathogens 
like LPS exert its effects [139]. The microarray results suggested that HDAC 
inhibitors influenced MAPK signaling.  
 
In addition, the common set of genes influenced by HDAC inhibitors also 
comprised those that modulate pro-inflammatory cytokines and chemokines, MMP 
secretion as well as angiogenesis. Hence, the subsequent experimental studies were 
designed according to data obtained from this microarray, with the intent to 
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investigate the effects of HDAC inhibitors on RASF proliferation, NF-κB and MAPK 
signaling pathways including their downstream effectors such as pro-inflammatory 
cytokine and NO secretion, angiogenesis, chemotaxis and bone and cartilage damage. 
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5.1 Materials and Methods 
5.1.1 Materials 
A. Cell Lines and Cell Culture Medium 
E11 cells were maintained in culture conditions as stated on page 50 of 
Chapter Three. THP-1 (TIB-202) cells, a human AML cell line was purchased from 
ATCC, USA [140]. They were maintained in RPMI 1640 supplemented with 20% 
FBS, 1% anti-biotic anti-mycotic solution, 0.05 mM 2-mercaptoethanol and incubated 
at 37
o
C with 5% CO2 [140]. RAW264.7 (TIB-71) cells, a murine macrophage cell line 
was purchased from American Type Culture Collection (ATCC, Manassas, VA 20108, 
USA) [28, 141]. They were maintained in DMEM supplemented with 10% FBS, 1% 
anti-biotic anti-mycotic solution and incubated at 37
o
C with 5% CO2 [28, 141]. 
 
B. NF-κB Assay 
 Enzyme linked immunosorbent assay (ELISA) kit for human NF-κB p65 
protein was purchased from Active Motif, Carlsbad, CA  92008, USA.  
 
C. Co-IP Analysis  
 A universal magnetic Co-IP kit was purchased from Active Motif, USA. For 
the Co-IP analysis to assess the interaction between p300 and NF-κB p65 as well as 
the interaction between MKP-1 and p38α, antibodies against p300, NF-κB p65, MKP-
1 and p38α were purchased from Santa Cruz Biotechnology, USA.  
 
D. Western Blot Analysis 
APS, 30% Acrylamide/ Bis (29:1), bromophenol blue, DTT and PVDF 
membranes were from Bio-Rad, USA. BSA was from Amresco Inc., USA. Glycerol 
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and glycine were from Biological Industries Ltd, Isreal. TEMED was from Sigma 
Aldrich, USA. Methanol was from Fisher, Singapore. NaCl was from LabScan, 
Poland. Proteinase inhibitor cocktail tablets were from Roche, USA. 10% SDS was 
from National University Medical Institute, Singapore. Tris buffers pH 7.4 and 8.0 
were from 1
st
 Base, Singapore. Primary antibodies against acetylated NF-κB were 
purchased from Abcam (Cambridge CB4 0FL, UK), p38α were purchased from Cell 
Signaling, (Danvers, MA 01923, USA), phosphorylated p38 (p-p38), MKP-1 and β-
actin were purchased from Santa Cruz Biotechnology, Inc., USA. Secondary 
antibodies which were either peroxidase conjugated ImmunoPure goat anti-mouse 
immunoglobulin (IgG) or goat anti-rabbit IgG and SuperSignal West Pico 
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A. NF-κB Assay 
E11 or THP-1 cells were seeded in 25mm
3
 culture flasks for 24 hr before 
varying concentrations of HDAC inhibitors (final concentration 1 nM – 50 µM) were 
added. After 1 hr, LPS (final concentration 5 μg/ml) was added and incubated for 
another 24 hr. Cells were lysed to obtain nuclear extracts. NF-κB p65 present in the 
nuclear extracts was quantified by ELISA, performed in accordance to manufacturer 
instructions. Optical densities were determined by a Genios plate reader at 450 nm 
and a reference wavelength of 655 nm. The optical density reading obtained is 
directly proportional to the amount of NF-κB p65 present in the tested nuclear extract. 
 
B. Co-IP Analysis for the Association between NF-κB p65 and p300 as well as the 
Association between MKP-1 and p38α 
E11 or THP-1 cells were seeded in 25 mm
3
 flasks and incubated for 24 hr 
before HDAC inhibitors (final concentration 50 nM) were added. After 1 hr, LPS 
(final concentration 5 μg/ml) was added and incubated for another 24 hr. For the 
interaction between p300 and NF-κB p65, cells were lysed to obtain nuclear extracts 
which were immunoprecipitated with antibody to p300. The immunoprecipitants were 
then immunobloted with antibody to NF-κB p65 and fractionated by SDS-PAGE. 
Bands were visualized by MultImage Light Cabinet.  
 
For the interaction between MKP-1 and p38α, the procedure was similar 
except immunoprecipitation with antibody to MKP-1 and immunoblotting with 
antibody to p38α. 
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C. Western Blot Analysis for the Distribution of Acetylated NF-κB as well as for 
MKP-1, p38α and p-p38 expression 
E11, RAW264.7 or THP-1 cells were seeded in 6 cm culture dishes and 
incubated for 24 hr before HDAC inhibitors (final concentration 50 nM) were added. 
After 1 hr, LPS (final concentration 5 μg/ml) was added and incubated for another 24 
hr. Cells were lysed to obtain both nuclear and cytoplasmic extracts. For distribution 
of acetylated NF-κB, proteins present in the extracts were separated by 12.5% SDS–
PAGE and transferred to PVDF membrane which was probed with primary antibodies 
against acetylated NF-κB p65 and β-actin followed by secondary antibodies 
(peroxidase conjugated ImmunoPure goat anti-mouse IgG or goat anti-rabbit IgG, 
Pierce Biotechnology, USA). SuperSignal West Pico Chemiluminescent Substrate 
(Pierce Biotechnology, USA) was added and bands were visualized by MultImage 
Light Cabinet.  
 
For MKP-1, p38α and p-p38 expression, the procedure was similar except 
probing with primary antibodies against MKP-1, p38α, p-p38 and β-actin. 
 
D. Calculations 
IC50 values were calculated using GraphPad Prism 5 Software (GraphPad 
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A. HDAC Inhibitors Inhibited LPS-induced NF-κB p65 Nuclear Accumulation in 
E11 RASF-like and THP-1 Monocyte-like Cells 
 As NF-κB plays an important role in RA pathogenesis [1], it was of interest to 
assess the impact of HDAC inhibitors on NF-κB. The inhibitory effects of HDAC 
inhibitors on NF-κB p65 nuclear accumulation were observed in E11 cells (Figure 5.1 
and Table 5.1). The baseline level of NF-κB p65 in nuclear extracts of control cells 
was minimal. LPS enhanced the nuclear accumulation of NF-κB p65 by about 15 
folds. However, in the presence of HDAC inhibitors at 100 nM, approximately 75% 
of the observed nuclear accumulation was inhibited. Similar results were obtained 
with THP-1 cells (Figure 5.2 and Table 5.2). Hence, HDAC inhibitors effectively 
inhibited NF-κB p65 nuclear accumulation in E11 cells at concentrations close to their 
anti-proliferative IC50s. However, further increases in the concentration of HDAC 
inhibitors to 500 nM or 1000 nM did not substantially suppress NF-κB p65 nuclear 
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Figure 5.1 HDAC inhibitors inhibited LPS-induced NF-κB p65 nuclear accumulation 
in E11 cells  
 
 
- : blank where cells were maintained in growth medium only.  
 
+: Raji nuclear extract was provided in the kit as a positive control for NF-κB 
activation. 
 
*** P < 0.001 versus LPS alone, by two-tailed unpaired t-test 
 
 
Table 5.1 IC50 values of HDAC inhibitors on NF-κB p65 nuclear accumulation 
inhibition in E11 cells 
 
 HDAC inhibitors 
 MS-275 PXD-101 SAHA TSA 
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Figure 5.2 HDAC inhibitors inhibited LPS-induced NF-κB p65 nuclear accumulation 
in THP-1 cells 
 
 
-: blank where cells were maintained in growth medium only.  
 
+: Raji nuclear extract was provided in the kit as a positive control for NF-κB 
activation. 
 
*** P < 0.001 versus LPS alone, by two-tailed unpaired t-test 
 
Table 5.2 IC50 values of HDAC inhibitors on NF-κB p65 nuclear accumulation 
inhibition in THP-1 cells 
 
 HDAC inhibitors 
 MS-275 PXD-101 SAHA TSA 
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B. HDAC Inhibitors Increased the Association between NF-κB p65 and p300  
 In order to determine whether NF-κB interacted with transcription co-activator 
p300, the nuclear extract of E11 cells was immunoprecipitated with p300 antibody 
and immunobloted with NF-κB p65 antibody. It was confirmed that NF-κB p65 
formed a complex with p300 transcriptional co-activator in E11 cells and THP-1 cells 
(Figure 5.3 and Figure 5.4). Moreover, HDAC inhibitors (final concentration 50 nM) 
increased the association between NF-κB and p300 (Figure 5.3 and Figure 5.4). 
 
Figure 5.3 HDAC inhibitors (final concentration 50 nM) increased the association 





Figure 5.4 HDAC inhibitors (final concentration 50 nM) increased the association 
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C. HDAC Inhibitor Increased Acetylated NF-κB p65 Accumulation in the 
Cytoplasm 
 In order to confirm the inhibitory effect of HDAC inhibitors on NF-κB p65 
nuclear accumulation, the distribution profile of acetylated NF-κB p65 within the 
nucleus and cytoplasm was assessed by western blot. There was little acetylated NF-
κB p65 in both the nucleus and cytoplasm of control cells. LPS increased acetylated 
NF-κB p65 localization in the nucleus. There was less acetylated NF-κB p65 in the 
nuclear fraction as compared to the cytoplasmic fraction when the cells were treated 
with HDAC inhibitors (final concentration 50 nM) in E11 and THP-1 cells. This is in 
line with results obtained from the NF-κB ELISA earlier where HDAC inhibitors 
were found to reduce NF-κB p65 nuclear accumulation significantly (Figure 5.5 and 
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Figure 5.5 HDAC inhibitors (final concentration 50 nM) increased acetylated NF-κB 




Figure 5.6 HDAC inhibitors (final concentration 50 nM) increased acetylated NF-κB 
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D. HDAC Inhibitor-Treated Cells Expressed more MKP-1 and less p38α  
          In order to investigate if HDAC inhibitors affected MKP-1 and p38α expression, 
western blot was performed. It was observed that p38 was expressed and activated 
(phosphorylated) in control cells (Figure 5.7). This was in agreement with the clinical 
observations [95]. LPS did not alter protein levels of p38 or p-p38 (Figure 5.7). 
However, HDAC inhibitors dramatically suppressed p38 expression and activation. 
MKP-1 was not detected in non-treated or LPS-stimulated E11 cells. On the other 
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Figure 5.7 HDAC inhibitor-treated cells expressed less p38α and p-p38 but more 
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E. HDAC Inhibitors Increased the Association between MKP-1 and p38α 
 In order to determine whether MKP-1 interacted with p38α, the nuclear 
extracts of E11, RAW264.7 or THP-1 cells were immunoprecipitated with MKP-1 
antibody and immunobloted with p38α antibody. It was confirmed that MKP-1 
formed a complex with p38α in the cells in the presence of HDAC inhibitors (Figure 
5.8). Of note, the complex was not detectable in control or LPS-stimulated cells 
(Figure 5.8).  
 
Figure 5.8 MKP-1 formed a complex with p38α in the presence of HDAC inhibitors 
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The NF-κB signaling pathway had been well studied. Key NF-κB members 
include p50/p105 and p52/p100 dimers, RelA/p65, RelB and c-Rel [142]. The 
transcription factor is implicated in inflammatory cascades that comprises of a myriad 
of genes during the onset of inflammation [1, 2, 142]. The genes encode for cytokines, 
MMPs and regulators of small molecule mediators [1, 2, 142]. Many biological and 
environmental factors can activate the NF-κB signaling pathway [142]. For instance, 
NF-κB activation can occur via cytokine stimulation (canonical pathway), TLR (non-
canonical pathway) or DNA damage and other forms of stress, initiating a signaling 
pathway that converges on an enzyme complex consisting of two inhibitor kappa B 
(IκB) kinases (IKKα and IKKβ) as well as a regulatory protein (IKKγ) that is required 
for IKK activation [1, 2, 142]. IKKs will phosphorylate IκBα at serine residues 32 and 
36, which target the inhibitor for ubiquitination and degradation by the 26S 
proteosome [142]. NF-κB activation in leukocytes recruited during the onset of 
inflammation was shown to be associated with pro-inflammatory gene expression 
[142]. Hence, NF-κB inhibition at the onset of inflammation can potentially result in 
decreased inflammatory responses. Data had suggested that NF-κB also played a role 
in inflammation resolution via leukocyte apoptosis regulation [142]. Due to its pivotal 
role in inflammation initiation and resolution, NF-kB is under the watchful eyes of 
pharmaceutical researchers looking for new therapies for autoimmune diseases like 
arthritis and lupus as well as cancer.  
 
 The impact of HDAC inhibitors on the pro-inflammatory transcription factor 
NF-κB has not been extensively studied and this information remains unavailable for 
RA. Furthermore, NF-κB is a non-histone target of HATs and HDACs and the impact 
CHAPTER FIVE – EFFECTS OF HDAC INHIBITORS ON 




of NF-κB acetylation on pro-inflammatory gene transcription also remains unclear. 
Therefore, the role of HDAC inhibitors with regards to NF-κB in RA-relevant cells 
and tissues has to be determined so that the functional connection between HDACs 
and NF-κB can be clarified to better evaluate potential applications of HDAC 
inhibitors in RA.  
 
In our study, HDAC inhibitors significantly inhibited NF-κB nuclear 
accumulation in both monocyte-like and RASF-like cells. NF-κB nuclear 
accumulation is an important step for NF-κB activation. To our knowledge, this is the 
first observation of inhibitory effects of HDAC inhibitors on NF-κB activation in 
RASFs. Furthermore, the levels for HDAC inhibitors to display anti-rheumatic 
activities such as anti-proliferation, pro-inflammatory cytokine and iNOS suppression, 
angiogenesis and matrix degradative enzyme down-regulation were all within the 
levels in which NF-κB activation was inhibited. Hence, inhibition of the NF-κB 
signaling pathway appeared to be a common mechanism for HDAC inhibitors to 
display their anti-rheumatic activities in RA models.  
 
NF-κB transcription factors normally form homo- and heterodimers with 
different DNA binding site specificities and DNA binding affinities [143, 144]. In the 
presence of certain biological or environmental stimuli, the activation of NF-κB 
dimers occurs through the degradation of IκB and NF-κB translocation into the 
nucleus [143, 144]. In the nucleus, NF-κB dimers then modulate the expression of 
genes such as those encoding cytokines, cell adhesion molecules, growth factors, 
immunoreceptors, other transcription factors and regulators of apoptosis [143, 144].  
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The suppressive effects of HDAC inhibitors on NF-κB-mediated gene 
expression might be mediated through the inhibition of HDAC3. Kiernan et al found 
that NF-κB can be acetylated by p300 at lysine residues 122 and 123 [144]. In 
addition, HDAC2 and HDAC3 also interacted with NF-κB p65 [144]. However, only 
HDAC3 was able to deacetylate NF-κB p65 [144]. NF-κB p65 acetylation reduced its 
binding to κB-DNA, aided its removal from DNA and facilitated IκBα-mediated 
export from the nucleus [144]. It was then proposed that NF-κB p65 acetylation 
played an important role in IκBα-mediated attenuation of NF-κB transcriptional 
activity [144]. Our results were in line with such a theory. Since HDAC inhibitors 
effectively inhibit HDACs, including HDAC3, acetylation on NF-κB was enhanced. 
Herein, Co-IP analysis showed that p65 can be acetylated by p300. HDAC inhibitors 
increased the association of NF-κB p65 to p300. Hence, HDAC inhibitors may 
decrease NF-κB-driven transcription by increasing NF-κB disposal to the cytoplasm. 
It was observed from our study that there was increased acetylated NF-κB p65 
accumulation in the cytoplasm as compared to the nuclei when cells were exposed to 
HDAC inhibitors. Subsequently, HDAC inhibitors could have decreased the 
transcription of downstream effectors which explained the decreased expression of 
COX-2, iNOS as well as secretion of NO and pro-inflammatory cytokines (IL-1β, IL-
6, IL-18 and TNF-α) and VEGF. Such observations are documented in Chapters Six 
and Seven. In all, HDAC inhibitors may achieve NF-κB suppression by increasing the 
acetylation of NF-κB p65 which increased the export of NF-κB to the cytoplasm. 
 
Noteworthy in some other studies, acetylation on NF-κB p65 lysine residue 
310 increased NF-κB-mediated gene expression [30, 31]. Under such circumstances, 
HDAC worked as a suppressor for NF-κB-mediated gene expression. Hence, HDAC 
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inhibitors may work as pro-inflammatory agents instead. However, the effects of 
HDAC inhibitors on NF-κB activation are dependent on cell type, stimulus and 
disease status [91]. The role of HDAC inhibitors in inflammatory diseases appeared to 
be a double edged. In some airway and microglial inflammatory diseases, HDAC 
inhibitors worked as inflammatory enhancers while in many other inflammatory 
conditions such as IBDs, RA and SLE, HDAC inhibitors displayed potent anti-
inflammatory activity [17-34, 91]. 
 
In addition, the MAPK pathway is important in TLR signaling, through which 
pathogens like LPS exert its effects [139]. MKP-1 regulates innate immune responses 
by inhibiting the MAPK pathway and decreasing TLR signaling [139]. MKP-1 could 
be acetylated by p300 on lysine residue K57 within its substrate-binding domain [139]. 
MKP-1 acetylation regulated its interaction with substrates to deactivate inflammatory 
signaling [139]. For instance, MKP-1 acetylation enhanced its interaction with p38 
thereby increasing its phosphatase activity to interrupt MAPK signaling [139]. 
Furthermore, the inhibition of deacetylases was shown to increase MKP-1 acetylation 
thus blocking MAPK signaling in wild type cells [139]. Hence, HDAC inhibitors 
were useful to reduce inflammation and mortality in mice treated with LPS [139]. It 
was then suggested that MKP-1 acetylation inhibited innate immune signaling [139]. 
Hence, the MAPK signaling pathway may be an important therapeutic target in the 
treatment of inflammatory diseases.  
 
Herein, it was found that HDAC inhibitors down-regulated p38α and p-p38 
expression while inducing MKP-1 expression. In addition, MKP-1 formed a complex 
with p38α in the presence of HDAC inhibitors. The increase in MKP-1 activity could 
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therefore interrupt MAPK signaling [139]. A decrease in MAPK signaling will also be 
beneficial as seen from the parallel decreases in LPS-induced NO secretion. A 
detailed discussion on the inhibitory effects of HDAC inhibitors on iNOS expression 
and NO secretion is illustrated in Chapter Seven. In all, it was found that HDAC 
inhibitors suppressed the MAPK signaling pathway by two mechanisms, namely 
down-regulation of p38 and induction of MKP-1, an endogenous p38 inhibitor. To 
our knowledge, this is the first study on the impact of HDAC inhibitors on p38 
MAPK signaling pathway in RASFs. Although, the anti-cancer activities of HDAC 
inhibitors were usually associated with p38 activation [145-147], current literature 
indicated that the effects of HDAC inhibitors on p38 relied on cell and the stimuli 
types [145-153]. 
 
Indeed, p38 inhibitors were deemed potential therapies for autoimmune 
diseases, including RA [148]. In fact, many p38 inhibitors are currently undergoing 
phase I/II trials for RA [148]. In addition, MKPs which are endogenous negative 
regulators of MAPK signaling, have received increasing recognition as modulators of 
inflammatory and immune responses [148]. Hence, they may be of therapeutic use in 
RA as well.  
 
Despite the potential of p38 inhibitors, there appears to be a lack of efficacy in 
RA [148]. Several reasons had been proposed. There could be inadequate exposure 
due to dose limitations imposed by toxicity in some p38α inhibitors such as X-702 
and pamapimod [148]. The drugs tend to be highly lipophillic and cross the blood 
brain barrier thus limiting their therapeutic efficacy except in nociception [148]. 
Hence, it was postulated that decreasing central nervous system entry might improve 
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the clinical endpoints in RA [148]. And although p38α is the most characterized 
isoform, specific p38 inhibitors might not fare well in RA management as all four p38 
isoforms are expressed in human synoviocytes and the RA synovium hence, each of 
them might contribute to RA [95, 149]. For instance, the β-isoform is required for 
chemokine production [150] but p38β-deficient mice were not resistant to arthritis 
[141]. So far, p38α has been described to be pro-inflammatory in nature. However, 
recent data also suggested that p38α may exhibit anti-inflammatory properties as it is 
required for IL-10 production in macrophages [151]. Therefore the use of a p38α 
inhibitor may counter the anti-inflammatory benefits of p38α [151]. Besides, p38 
blockade itself may not be able to switch off compensatory effects by other upstream 
kinases [148]. For instance, MKK3, MKK6 and transforming growth factor-β 
activated kinase-1 can regulate NF-κB on their own [92, 154]. In vivo models used to 
study p38 inhibition also had to be carefully chosen as the kinetics of MAPK 
activation in CIA mice does not correlate with RA [155]. In humans, the decreases in 
C-reactive protein were transient although drug levels were adequate, suggesting that 
humans may have a physiological escape mechanism from p38 inhibition [148].  
 
As the inflammatory signal networks of RA are highly redundant and complex, 
blocking a downstream pathway such as MAPK may be insufficient to fight RA [155]. 
Therefore, it may be more practical to work on upstream pathway(s) or decrease the 
selectivity of inhibitors [155]. One class of such promiscuous inhibitors is the HDAC 
inhibitors.  They have emerged as novel anti-cancer therapies [91]. However, they had 
also demonstrated anti-inflammatory and anti-rheumatic benefits in models of arthritis 
[91].  Rahman et al found that HDAC inhibitors like NaB and TSA reduced RANKL 
or TNF-α-induced osteoclast differentiation by inhibiting NF-κB nuclear translocation 
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and the expression of p-p38 [101]. Hence, HDAC inhibitors had the advantage of 
affecting both NF-κB and MAPK signaling pathways [101].  
 
Indeed, our results showed that HDAC inhibitors modulated both NF-κB and 
MAPK signaling pathways in RASFs. MAPK inhibition was attributed to decreased 
p38 expression and MKP-1 activation which is in line with previous studies [101]. 
Besides taking part in the regulation of MAPK pathway, the acetylation and 
phosphorylation of histones were also associated with the transcriptional activation of 
MKP-1 [101]. The treatment of RASFs with HDAC inhibitors induced MKP-1 and 
reduced p38 expression here. Moreover, HDAC inhibitors can modulate post-
translational acetylation of various non-histone proteins [91]. Clearly, HDAC 
inhibitors displayed anti-rheumatic activities via multiple mechanisms [91]. The 
multiple-prong approach employed by HDAC inhibitors fit the bill of ‘decrease the 
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6.1 Materials and Methods 
6.1.1 Materials 
A. Cell Lines and Cell Culture Medium 
E11 cells were maintained in culture conditions as stated on page 50 of 
Chapter Three. THP-1 (TIB-202) and RAW264.7 cells were maintained in culture 
conditions as stated on page 91 of Chapter Five.  
 
B. Hydrocortisone (HYD) and BAY 11-7082 
HYD was from Pharmacia, Milton Keynes, MK5 8PH, UK. Bay 11-7082, an 
inhibitor of IκB phosphorylation and NF-κB activation [156], was purchased from 
Sigma Aldrich, USA. 
 
C. ELISA Sets 
ELISA sets for human IL-1β, IL-6, TNFα (BD Biosciences, New Jersey 07417, 
USA) and IL-18 (Bender MedSystems, A-1030 Vienna, Austria) were purchased.  
 
D. NO Assay 
Griess reagent, LPS (Escherichia coli 055:B5) and sodium nitrite (NaNO3) 
were purchased from Sigma Aldrich, USA. SB203580 (Calbiochem, San Diego, CA 
92121, USA), a known p38 MAPK inhibitor [157], was purchased. 
 
E. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)  
Primers for COX-2, iNOS and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), Tris buffers pH 6.8 and 8.8 were purchased from First Base, Singapore. 
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RNeasy mini kit (Qiagen, Germantown, MD 20874, USA), RevertAid first strand 
cDNA synthesis kit (Fermentas, Berlington, Canada), dNTP nucleotides and Taq 
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A. Cytokine Secretion 
E11 or THP-1 cells were seeded in 24-well plates and incubated for 24 hr 
before varying concentrations of HDAC inhibitors (final concentration 1 nM – 1 µM) 
or HYD (final concentration 1 µM) were added. HYD served as a positive control. 
After 1 hr, LPS (final concentration 5 μg/ml) was added and incubated for another 24 
hr. IL-1β, IL-6, IL-18 and TNF-α secreted into supernatant were quantified by 
individualized ELISA, performed in accordance to manufacturer instructions. Optical 
densities were determined by a Genios plate reader at 450 nm and reference 
wavelength of 650 nm. The optical density obtained is directly proportional to the 
amount of respective cytokine secreted into the media. To determine the impact of 
NF-κB on the secretion of these inflammatory cytokines, the effects of BAY 11-7082, 
a well-known NF-κB inhibitor [156] at 1, 2.5 and 5 µM were also investigated. 
 
B. NO Assay 
E11 or RAW264.7 cells were seeded in 24-well plates and incubated for 24 hr 
before varying concentrations of HDAC inhibitors, MTX (final concentration 1 nM – 
25 µM) or SB203580 (final concentration 1 – 5 μM) were added. After 1 hr, LPS 
(final concentration 5 μg/ml) was added and incubated for another 24 hr. The 
accumulation of nitrite in the supernatant was taken to be an indicator for iNOS 
activity. Nitrite levels were determined by adding an equivalent volume of Griess 
reagent and let stand for 10 min at room temperature. Optical densities were 
determined by a Genios plate reader at 540 nm. An external standard calibration curve 
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was established using known concentrations of NaNO3 ranging 1 to 100 μM. Hence, 
unknown concentrations of NO in the samples can be determined from the calibration. 
 
C. Interaction between HDAC Inhibitors and MTX 
Since both HDAC inhibitors and MTX proved to be effective in NO inhibition, 
it was of interest to investigate if interaction exists between HDAC inhibitors and 
MTX when used in combination. MTX was chosen as it is the gold standard DMARD 
used in RA. The median-drug effect analysis method by Chou and Talalay [130] has 
been widely used for the evaluation of potential interaction between different agents. 
Drug interaction is assessed by calculating the combination index (CI) at a series of 
values of fraction of the cells affected (fa).  
 
E11 or RAW264.7 cells were seeded in 24-well plates and incubated for 24 hr. 
In order to evaluate the interaction between the two drugs, the medium was aspirated 
and replaced with a combination of HDAC inhibitors and MTX in a fixed IC50-based 
molar concentration ratio. A HDAC inhibitor: MTX ratio of 5: 3 was chosen based on 
the IC50 values obtained from cell proliferation studies performed earlier. NO assay 
was again performed.  
 
For agents that are mutually non-exclusive, i.e. they possess different 
mechanisms of action or are acting independently. The CI is calculated by the 
equation as stated in Chapter Three. By repeating the calculations at various effect 
levels, a median-drug-effect plot can be constructed by plotting CI versus fa. 
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D. RT-PCR Analysis for COX-2 and iNOS Expression 
E11 cells were seeded in 6 cm culture dishes and incubated for 24 hr before 
HDAC inhibitors (final concentration 100 nM) were added. After 1 hr, LPS (final 
concentration 5 μg/ml) was added and incubated for 24 hr. RNA was extracted using 
the RNeasy mini kit. Optical density for each sample of RNA was measured at 260 
and 280 nM using NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, DE, 
USA). All RNA samples isolated had OD 260/280 ratio > 1.8 to ensure that the 
samples were free from protein contamination. All RNA samples isolated also had 
OD 260/230 ratio > 1.8 to ensure that the samples were free from organic component 
or salt contamination. First strand cDNA was manufactured using RevertAid First 





primers used were: 
 
COX-2: 5’-GGTCTGGTGCCTGGTCTGATGATG- 3’ (sense)  
5’-GTCCTTTCAAGGAGAATGGTGC- 3' (anti-sense) 
 
iNOS:  5’-ATGCCAGATGGCAGCATCAGA- 3’ (sense) 
5’-TTTCCAGGCCCATTGTCCTGC- 3’ (anti-sense) 
 
GAPDH: 5’-TGATGACATCAAGAAGGTGGTGAAG- 3’ (sense)  
5’-TCCTTGGAGGCCATGTGGGCCAT- 3’ (anti-sense) 
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The RT-PCR analyses for COX-2 were performed with its primers in a 25 µl 
reaction
 
mixture (2.5 units of AmpliTaq DNA polymerase, 0.2 mM dNTP, 50 mM 
KCl, 2 mM MgCl2, 1 μg of cDNA, 400 nM
 
primers and 10 mM Tris buffer pH 8.3) 
for 35 cycles consisting denaturation at 94°C
 
for 20 sec, annealing at 52°C for 20 sec, 
extension at 72°C
 
for 30 s and final extension at 72°C for 10 min. The conditions for  








Resultant mRNA was mixed with loading dye and resolved using a 0.1% (w/v) 
agarose gel at 80 V for 1 h. After which, the gel was incubated with ethidium bromide 
for 15 min before visualizing with Gel Doc XR system (Bio-Rad, Hercules, CA 
94547, USA). Band densitometry was performed using ImageJ Version 1.42. Relative 
intensities of treatment with respect to control bands were obtained by comparing the 
intensities of bands obtained from cells treated with LPS or HDAC inhibitors to that 
from control cells. 
 
E. Calculations 
 IC50 values were calculated using GraphPad Prism 5 Software (GraphPad 
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A. HDAC Inhibitors Suppressed Pro-Inflammatory Cytokines in E11 RASF-like 
and THP-1 Monocyte-like Cells in a Concentration-Dependent Manner 
In order to investigate if HDAC inhibitors affected cytokine secretion, ELISAs 
were performed. HDAC inhibitors suppressed IL-1β, IL-6, IL-18 and TNF-α in THP-
1 cells in a concentration-dependent manner (Figure 6.1 (A) – (D) and Table 6.1). The 
suppression was achievable at sub-micromolar levels (Figure 6.1 (A) – (D) and Table 
6.1). Noteworthy, IL-18 secretion was more sensitive to HDAC inhibitor treatment in 
THP-1 cells as secretion was inhibited by more than 50% with 1 nM of HDAC 
inhibitors. In comparison, HYD (1 µM), a clinically active anti-inflammatory 
glucocorticoid, suppressed IL-1β, IL-6, IL-18 and TNF-α by 85%, 40%, 60% and 
80%, respectively (Figure 6.1 (A) – (D)). BAY 11-7082 also suppressed IL-1β, IL-6, 
IL-18 and TNF-α in THP-1 cells in a concentration-dependent manner. At 1, 2.5 and 5 
µM, BAY 11-7082 suppressed IL-1β by 76.22 ± 2.2%, 82.7 ± 1.7%, 93.6 ± 1.3% 
(mean ± SD, n= 4), respectively; suppressed IL-6 by 73.3 ± 2.2%, 86.0 ± 2.0%, 92.4 
± 1.0% (mean ± SD, n= 4), respectively; suppressed IL-18 by 83.0 ± 2.2%, 92.4 ± 
1.0%, 95.5 ± 1.9% (mean ± SD, n= 4), respectively; suppressed TNF-α by 65.8 ± 
2.2%, 72.3 ± 1.9%, 83.3 ± 1.5% (mean ± SD, n= 4), respectively (Figure 6.2). 
 
In addition, HDAC inhibitors suppressed IL-6 and IL-18 in E11 cells in a 
concentration-dependent manner (Figure 6.3 (A) & (B) and Table 6.2). Noteworthy, 
IL-18 secretion was also more sensitive to HDAC inhibitor treatment in E11 cells as 
secretion was inhibited by more than 50% with 1 nM of HDAC inhibitors. In 
comparison, HYD suppressed IL-6 and IL-18 by about 50% compared to control E11 
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cells (Figure 6.3 (A) & (B)).  BAY 11-7082 also suppressed IL-6 and IL-18 in E11 
cells in a concentration-dependent manner. At 1, 2.5 and 5 µM, BAY 11-7082 
suppressed IL-6 by 68.2 ± 2.2%, 80.5 ± 1.9%, 86.8 ± 1.0% (mean ± SD, n= 4); 
suppressed IL-18 by 65.5 ± 1.3%, 78.0 ±1.6%, 84.3 ± 1.7% (mean ± SD, n= 4), 
respectively (Figure 6.4). Clearly, blockade of NF-κB signaling pathway displayed 
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Figure 6.1 HDAC inhibitors suppressed IL-1β, IL-6, IL-18 and TNF-α in THP-1 cells 
in a concentration-dependent manner 
 









CHAPTER SIX – EFFECTS OF HDAC INHIBITORS ON 

















CHAPTER SIX – EFFECTS OF HDAC INHIBITORS ON 

















CHAPTER SIX – EFFECTS OF HDAC INHIBITORS ON 











Table 6.1 IC50 values of HDAC inhibitors on pro-inflammatory cytokine inhibition in 
THP-1 cells. 95% confidence intervals are listed within the parentheses. 
 
 HDAC inhibitors 











(86 – 120) 
 
26 
(20 – 34) 
 
IL-6  20 
(16 – 24) 
22 
(16 – 21) 
51 
(43 – 61) 
11 
(10 – 13)  
 
IL-18  <1 
 
<1 <1 <1 
 
TNF-α 8 
(7 – 9) 
19 
(16 – 22) 
53 
(45 – 64) 
11 
(9 – 13) 
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Figure 6.2 BAY 11-7082 suppressed IL-1β, IL-6, IL-18 and TNF-α in THP-1 cells in 
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Figure 6.3 HDAC inhibitors suppressed IL-6 and IL-18 in E11 cells in a 
concentration-dependent manner 
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Table 6.2 IC50 values of HDAC inhibitors on pro-inflammatory cytokine inhibition in 
E11 cells 
 
 HDAC inhibitors 
















IL-18  <1 <1 <1 <1 
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B. HDAC Inhibitors Suppressed NO in E11 RASF-like and RAW264.7 
Macrophage-like Cells in a Concentration-Dependent Manner 
In order to investigate if HDAC inhibitors affected NO secretion, Griess 
assays were performed. Non-stimulated RAW264.7 cells secreted little NO while 
non-stimulated E11 cells secreted high levels of NO. NO increased when both cell 
types were stimulated with LPS, consistent with previous reports [158, 159]. Of note, 
E11 cells had high baseline NO secretion (about 250 µM) and LPS could only 
increase it by about 1 fold over the control cells. At sub-micromolar levels, HDAC 
inhibitors suppressed NO in RAW264.7 cells in a concentration-dependent manner 
(Figure 6.5 and Table 6.3). HDAC inhibitors were more potent in inhibiting NO in 
E11 cells than in RAW264.7 cells as the inhibition exceeded 50% even at 1 nM 
(Figure 6.6 and Table 6.4). SB203580, a known p38 MAPK inhibitor [157], also 
inhibited LPS-induced NO in both E11 and RAW264.7 cells in a concentration-
dependent manner (Figure 6.7). At 1, 5 and 10 µM, SB203580 inhibited NO in 
RAW264.7 cells by 51.9 ± 3.6%, 64.3 ± 2.6% and 76.7 ± 2.2% (mean ± SD, n= 6), 
respectively. At 1, 5 and 10 µM, SB203580 also inhibited NO in E11 cells by 66.1 ± 
0.2%, 78.0 ± 2.1% and 84.7 ± 2.4% (mean ± SD, n= 6), respectively. Clearly, 
blockade of p38 MAPK pathway by SB203580 displayed anti-inflammatory activities 
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Table 6.3 IC50 values of HDAC inhibitors on NO inhibition in RAW264.7 cells. 95% 
confidence intervals are listed within the parentheses. 
 
 HDAC inhibitors MTX 
 MS-275 PXD-101 SAHA TSA  
 
 IC50 values (nM) 
 
20 
(17 – 23) 
 
19 
(15 – 23) 
 
45 
(38 – 53) 
 
41 

















CHAPTER SIX – EFFECTS OF HDAC INHIBITORS ON 









Table 6.4 IC50 values of HDAC inhibitors on NO inhibition in E11 cells 
 
 HDAC inhibitors 
 MS-275 PXD-101 SAHA TSA 
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C. Combination of HDAC Inhibitor with MTX can be Synergistic for NO 
Suppression 
Since both HDAC inhibitors and MTX suppressed NO, it was of interest to 
determine the interaction between HDAC inhibitor and MTX when used in 
combination. Median effect analysis over a range of HDAC inhibitor and MTX 
concentrations, administered at fixed IC50 ratio of 5: 3, yielded CI values less than 1 
for the combinations of HDAC inhibitors with MTX in E11 or RAW264.7 cells. This 
denoted synergistic interactions between HDAC inhibitors and MTX for NO 
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Figure 6.8 Median-drug-effect plots for the combinations of HDAC inhibitors with 
MTX in RAW264.7 cells 
 
 
Table 6.5 Combination indices for the drug combinations in RAW264.7 cells 
 


















0.2 0.00140 < 0.001 < 0.001 < 0.001 
0.3 0.00208 0.00190 < 0.001 0.00112 
0.4 0.00296 0.00388 0.00212 0.00222 
0.5 0.00419 0.00746 0.00481 0.00414 
0.6 0.00609 0.0143 0.0115 0.00774 
0.7 0.00943 0.0293 0.0318 0.0153 
0.8 0.0167 0.0699 0.123 0.0352 
0.9 0.0426 0.259 1.14 0.123 
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Figure 6.9 Median-drug-effect plots for the combinations of HDAC inhibitors with 
MTX in E11 cells 
 
 
Table 6.6 Combination indices for drug combinations in E11 cells 
 


















0.2 < 0.001 < 0.001 < 0.001 < 0.001 
0.3 < 0.001 < 0.001 < 0.001 < 0.001 
0.4 < 0.001 < 0.001 < 0.001 < 0.001 
0.5 < 0.001 < 0.001 < 0.001 < 0.001 
0.6 < 0.001 < 0.001 < 0.001 < 0.001 
0.7 < 0.001 < 0.001 < 0.001 < 0.001 
0.8 < 0.001 < 0.001 < 0.001 < 0.001 
0.9 0.0391 0.641 0.180 0.0435 
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D. HDAC Inhibitors Reduced COX-2 and iNOS Expression in E11 Cells 
Since HDAC inhibitors suppressed NO secretion, it was of interest to 
determine if it was due to modulation in iNOS expression. iNOS was found to be 
expressed in E11 cells constitutively and LPS could augment its transcription. HDAC 
inhibitors worked at transcriptional level to inhibit iNOS expression (Figure 6.10 and 
Table 6.7). These results were in good accord to the NO secretion data (Figure 6.6 and 
Table 6.4). Similarly, COX-2 was also expressed in E11 cells and LPS increased its 
transcription. However, HDAC inhibitors were able to reduce its transcription (Figure 
6.10 and Table 6.7). 
 




Table 6.7 Relative densitometry readings 
Relative densitometry 













iNOS 2.97 0.55 0.85 0.31 0 
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Cytokines are implicated at every stage of RA pathogenesis [2, 3]. It was 
observed in animals that an imbalance in pro- and anti-inflammatory cytokines in the 
diseased joint results in autoimmunity, chronic inflammation and eventual joint 
damage [2, 3]. In RA, cytokines such as IL-1, IL-6 and TNF- work synergistically to 
stimulate adhesion-molecule expression, cell proliferation, other cytokines, MMPs 
and prostaglandins [2, 3]. Hence, cytokines provide the link between immune 
regulation and tissue destruction in RA [2, 3].  
 
Multiple cells including B cells, T cells, macrophages, monocytes, 
chondrocytes and osteoclasts are involved in RA [160]. Drugs have been developed to 
counter the deleterious effects generated by these cells. B cells are required for auto-
antibody production, resulting in immune complex formation and production of 
down-stream cytokines like IL-6, IL-10 and leukotriene-β in RA [160]. Rituximab by 
Genetech Inc. is a CD20 specific monoclonal antibody that depletes all B cell subsets 
to provide long-lived clinical benefits [161]. However, there had been concerns about 
the risk for infections with rituximab as immunization responses to neoantigens and 
polysaccharides are diminished upon therapy [161]. However, recall antibody and 
delayed-type hypersensitivity responses were found to be intact hence infection rates 
were not observed to increase during sequential therapy with rituximab or other 
biologics [161-163]. Controlled trials are still ongoing to assess the safety of other 
biologics when used with rituximab. T cells are needed to associate with major 
histocompatibility complex class II alleles and a large number of these cells reside in 
the inflamed synovium in animal models of disease [161]. Therapeutics modulating  
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T cells, such as cyclosporine and CD52 antibody such as alemtuzumab (Campath®) 
by Schering AG offered dismal results [164, 165]. Macrophages are essential sources 
of synovial pro-inflammatory cytokines. Their activation often occurs via TLRs that 
recognize microbial products like LPS [164]. Monocytes had been found to produce 
IL-6 which was required for CIA induction [161]. In addition, the differentiation of 
osteoclasts from their precursors was dependent on RANKL and GM-CSF [161]. 
Fortunately, anti-IL-1 and -TNF- biologics had been approved for RA treatment, 
with more undergoing clinical trials [2, 3]. TNF-α blockade yields responses in 
approximately 70% of patients with the decline in plasma IL-6 and acute phase 
proteins occurring quickly in about 24 hr to reduce leukocyte migration and 
endothelial cell activation [2, 3]. Though promising, anti-IL-1 and -TNF- biologics 
utilization also faces some controversy and limitations. 
 
TNF-α is important for normal immune responses but its overproduction had 
been linked to excessive inflammation and even joint damage in RA [2, 3]. 
Medications that neutralize TNF-α are useful and have been routinely used to control 
RA and other inflammatory diseases [2, 3]. TNF blockade had offered much hope for 
RA treatment however they can also suppress the body’s natural defenses hence 
increasing the vulnerability to infections and malignancy [167-169].  
 
Among the important side effects of TNF-α inhibitors are an increased risk of 
reactivating latent tuberculosis infection, developing a new tuberculosis infection or 
non tuberculous mycobacterial pulmonary infection [167-170]. As a result, 
prescreening for latent tuberculosis infection with a tuberculin skin test is necessary 
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before initiating TNF-α inhibitor therapy [167, 168]. In 2008, FDA directed 
manufacturers of TNF-α blockers like infliximab (Remicade®), etanercept (Enbrel®), 
adalimumab (Humira®), certolizumab pegol (Cimzia®) to strengthen the existing 
warnings on fungal infections associated with the use of TNF-α inhibitors [171] as it 
was noted that health care providers are still consistently not recognizing cases of 
histoplasmosis and other invasive fungal infections leading to delayed treatment and 
deleterious outcomes [171].  
 
In 2009, FDA again directed manufacturers of infliximab (Remicade®), 
etanercept (Enbrel®), adalimumab (Humira®), certolizumab pegol (Cimzia®) and 
golimumab (Simponi®) to highlight heightened cancer risks especially lymphoma, in 
children and adolescents [172]. The new warnings were instituted after an 
investigation into reports of cancer in children and young adults submitted to the 
FDA’s Adverse Event Reporting System over a 10 year period [172]. It was found 
that TNF-α blockers increased cancer risk and cancers tend to appear at approximately 
30 months after the commencement of treatment [172]. About half of the cancers 
were lymphomas which involves cells of the immune system [172]. Some of the 
cancers were fatal [166]. Kahn et al reported that lymphomas tend to develop early 
within the first year of anti-TNF-α therapy but the incidence plateaus with time [173]. 
The initial early peak in lymphoma occurrence was attributed to TNF-α inhibitors 
unmasking or accelerating lymphomas that already exist [173]. The numbers 
diminished over time due to the reduction in RA disease activity [173]. Therefore, it 
was suggested that future studies on lymphoma risk in RA patients should consider 
incorporating some form of prescreening examination for lymphoma before initiating 
TNF-α inhibitor therapy [173]. 
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Here, the anti-inflammatory potential of HDAC inhibitors was demonstrated 
as they were able to suppress pro-inflammatory cytokines like IL-1β, IL-6, IL-18 and 
TNF-α released from THP-1 monocyte-like and E11 RASF-like cells. Hence, HDAC 
inhibitors are exciting alternative avenues to explore in terms of their anti-
inflammatory and anti-rheumatic potential, when current RA therapy is sub-optimal. 
Coupled with the uncertainty over biologic agents resulting in serious adverse effects 
including lymphomas, HDAC inhibitors may offer an additional advantage as they are 
originally developed as anti-cancer agents. 
 
Results also revealed that the HDAC inhibitors suppressed NO secretion in 
both macrophage-like and RASF-like cells. In fact, HDAC inhibitors were about 20 
folds more effective than MTX in reducing NO. In cell proliferation assays, MTX had 
an IC50 value comparable to the HDAC inhibitors. However, MTX was significantly 
weaker than the HDAC inhibitors at NO inhibition. It might be explained that MTX 
could have exerted effects on NO mainly via cytotoxicity. This was confirmed by 
tryphan blue exclusion and LDH cytotoxicity assay where MTX caused significant 
cytotoxicity. In contrast, there was minimal cytotoxicity in HDAC inhibitor-treated 
cells at similar concentrations.  
 
The combination of HDAC inhibitors and DMARDs may be advantageous in 
RA management as conventional RA treatment with a single DMARD usually fails to 
control symptoms or disease progression adequately [3]. It was found that 
combination of HDAC inhibitors and MTX can be synergistic in reducing NO 
production. In addition, SB203580 (a known p38 MAPK inhibitor) [157] inhibited 
LPS-induced NO in both E11 and RAW264.7 cells in a concentration-dependent 
CHAPTER SIX – EFFECTS OF HDAC INHIBITORS ON 




manner. It implied that NO secretion is at least dependent on p38 MAPK signaling 
pathway though other pathways may be involved. Since HDAC inhibitors also 
inhibited NO, this may in part be contributed by p38 MAPK inhibition. The effects of 
HDAC inhibitors on MAPK signaling pathway had been studied and results had been 
illustrated with greater detail in Chapter Five. 
 
As HDAC inhibitors suppressed NO, it was of interest to determine if the 
suppression was due to iNOS modulation since NO is regulated by iNOS [159]. At 
the same time, COX-2 expression was monitored as COX-2 is an angiogenesis 
mediator with activities up-regulated in the RA synovium [166]. HDAC inhibitors 
were shown to reduce LPS-induced COX-2 expression at transcription level. It was 
also found that HDAC inhibitors reduced LPS-induced iNOS expression at 
transcription level. Hence, HDAC inhibitors could have suppressed NO secretion as a 
result of reduced iNOS expression. The effects of HDAC inhibitors on NO and iNOS 
also correlated well with anti-inflammatory activities in various disease models such 
as diabetes, SLE and stroke [21, 38, 91]. In addition, the reduction in COX-2 and 
iNOS expression will be beneficial in RA as there can be less angiogenesis and 
inflammation.  
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7.1 Materials and Methods 
7.1.1 Materials 
A. Cell Lines and Cell Culture Medium 
E11 cells were maintained in culture conditions as stated on page 50 of 
Chapter Three. THP-1 cells were maintained in culture conditions as stated on page 
91 of Chapter Five. U937 (CRL-1593.2), a human AML cell line was purchased from 
ATCC, USA [14]. They were maintained in RPMI 1640 supplemented with 10% FBS, 
1% anti-biotic anti-mycotic solution and incubated at 37
o
C with 5% CO2 [14]. Human 
umbilical vein endothelial cells (HUVEC, CRL-2873) were purchased from ATCC, 
USA. They were maintained in DMEM supplemented with 20% FBS, 1 % anti-biotic 
anti-mycotic solution and incubated at 37
o
C with 5% carbon CO2 [108]. 
 
B. VEGF Assay 
ELISA set for human VEGF was purchased from Bender MedSystems, 
Austria.  
 
C. HUVEC Angiogenesis Assay 
 Matrigel was purchased from BD Biosciences, USA. 
 
D. Chemotaxis under Agarose  
Absolute methanol was from Fisher, Singapore. Agarose powder, 37% 
formaldehyde, Field's stain and HEPES solution were from Sigma Aldrich, USA.  
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E. Chemokine ELISA  
Human GCP-2 and MCP-2 chemokine ELISA sets were purchased from 
Antigenix America Inc. (Huntington, NY11746, USA) while that for MIF was 
purchased from R & D Systems (McKinley Place NE, MN 55413, USA). Bay 11-
7082, an inhibitor of IκB phosphorylation and NF-κB activation [156], was purchased 
from Sigma Aldrich, USA. 
 
F. Substrate Gel Zymography 
30% Acrylamide/ Bis (29:1), coomasie blue and triton-X were from Bio-Rad, 
USA. 10% SDS was from National University Medical Institute, Singapore. APS, 
CaCl2, TEMED and bovine gelatin were from Sigma Aldrich, USA. Acetic acid and 
methanol were from Fisher, Singapore. NaCl was from BDH Laboratory Supplies, 
Poland. Glycerol was from Biological Industries Ltd, Israel.  Tris buffers pH 6.8, 7.4 
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A. VEGF Assay 
E11 cells were seeded in 24-well plates and incubated for 24 hr before varying 
concentrations of HDAC inhibitors (final concentration 1 nM – 1 µM) or HYD (final 
concentration 1 µM) were added. After 1 hr, the cells were incubated with a 
combination of IL-6 (final concentration 100 ng/ml), soluble IL-6 receptor (sIL-6R, 
final concentration 100 ng/ml) and IL-1β (final concentration 5 ng/ml) for another 24 
hr [174]. VEGF secreted into the supernatant was quantified using ELISA, performed 
in accordance to manufacturer instructions. Optical densities were read with Genios 
plate reader at 450 nm and a reference wavelength of 620 nm. 
 
B. HUVEC Angiogenesis Assay 
 150 µl of matrigel without growth factor was placed into each well of 48-well 
plates. It was allowed to polymerize by incubating at 37
o
C for 1 hr. After which, 
HUVECs (2 × 10
4
 cells) were seeded onto the matrigel in 270 µl of DMEM, 
supplemented with 20% FBS, VEGF (final concentration 100 ng/ml) and the 
respective HDAC inhibitors (final concentration 100 nM). These were incubated for 
24 hr at 37
o
C with 5% carbon CO2. Three different microscopic fields at × 40 
magnification were viewed for each sample using an inverted microscope (Leica 
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C. Chemokine ELISA  
E11 cells were seeded in 96-well plates and incubated for 24 hr before varying 
concentrations of HDAC inhibitors (final concentration 1 – 1000 nM) were added. 
After 1 hr, LPS (final concentration 5 μg/ml) was added and incubated for another 24 
hr. GCP-2, MCP-2 and MIF were quantified by individualized ELISA, performed in 
accordance to manufacturer instructions. Optical densities were determined by a 
Genios plate reader at 450 nm and a reference wavelength of 650 nm. The optical 
density obtained is directly proportional to the amount of respective chemokine 
secreted into the media. 
 
Bay 11-7082 is an inhibitor of IκB phosphorylation and NF-κB activation 
[154]. It was used to determine if chemokine production is NF-κB dependent. Hence, 
E11 cells were seeded in 96-well plates and incubated for 24 hr before Bay 11-7082 
(final concentration 1 – 5 μM) was added. After 1 hr, LPS (final concentration 5 g/ml) 
was added and incubated for another 24 hr. GCP-2, MCP-2 and MIF were quantified 
by ELISA, performed in accordance to manufacturer instructions. Optical densities 
were determined by a Genios plate reader at 450 nm and a reference wavelength of 
650 nm. 
 
D. Chemotaxis under Agarose 
 The assay was based on a protocol developed by Robert DN et al [175]. A 
series of three wells (2.4 mm in diameter and 2.4 mm apart) were cut in a 6 cm culture 
dish containing agarose gel 2.4% (w/v). The centre well of each three well series 
received 10 μl of THP-1 or U937 cell suspension (2 × 105 cells/ ml). The chemotactic 
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medium well received 10 μl of chemotatic medium, which is the supernatant derived 
from E11 cells cultured in the presence of LPS (5 μg/ml) only or LPS and HDAC 
inhibitors (100 nM) for 24 hr. The remainder well received 10 μl of fresh medium 
which is deemed to be non-chemotactic. After which, the completed dishes were 
incubated at 37
o
C for 24 hr. Cells were fixed by adding absolute methanol followed 
by 37% formaldehyde for 30 min each. After fixation, the plates were stained with 
Field's stain and air dried. The number of cells which migrated into chemotactic and 
fresh medium wells was counted under an inverted microscope (Leica). The number 
of cells which distributed into the chemotactic medium and fresh medium wells was 
counted and compared using chi-square test. 
 
E. Substrate Gel Zymography for MMP-2 and MMP-9 Expression in E11 cells 
E11 cells were seeded in 25mm
3
 culture flasks and incubated for 24 hr before 
HDAC inhibitors (final concentration 100 nM) were added. After 1 hr, LPS (final 
concentration 5 μg/ml) was added and incubated for another 30 minutes. One part of 
the medium was mixed with one part of sample buffer (0.1% bromophenol blue, 
glycerol, 10% SDS and 0.5 M Tris-HCl pH 6.8) and let stand for 10 min at room 
temperature. Samples were mixed with SDS loading buffer (0.02% bromophenol blue, 
0.2 M DTT, 20% glycerol, 10% SDS and 0.25 M Tris-Cl pH 6.8). Subsequently, they 
were resolved by a 10% SDS–PAGE gel, containing 0.2% (w/v) gelatin at 100V for 1 
hr. After the run, the gel was incubated with a renaturing buffer (25% triton-X in PBS) 
and gently agitated for 1 hr at room temperature. Then the renaturing buffer was 
decanted and replaced with developing buffer (5 mM CaCl2, 200 mM NaCl and 50 M 
Tris-HCl pH 7.4). The gel was equilibrated in developing buffer for 30 min at room 
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temperature with gentle agitation before replacement with fresh developing buffer and 
incubated overnight at 37
o
C. It was then stained with coomassie blue 0.5% (w/v) for 
30 min before destaining with acetic acid, methanol and water (10: 50: 40). Areas of 
protease activity would appear as clear bands against a dark background where 
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A.  HDAC Inhibitors Down-Regulated VEGF in E11 RASF-like Cells in a 
Concentration-Dependent Manner 
Angiogenesis is involved in RA pathogenesis [2, 57]. As VEGF is a key 
regulator of angiogenesis and is expressed in RASFs [2], the impact of HDAC 
inhibitors on VEGF was investigated in E11 cells. The secretion of VEGF from E11 
cells was stimulated by a combination of IL-6, sIL-6R and IL-1β. It was found that 
HDAC inhibitors inhibited VEGF secretion in a concentration-dependent manner 
(Figure 7.1 and Table 7.1). Interestingly, at 1 nM, they exhibited potencies ranging 30 
– 40% inhibition. The aforementioned could only be achieved by HYD at 1 µM 
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Figure 7.1 HDAC inhibitors down-regulated VEGF in E11 cells in a concentration-






Table 7.1 IC50 values of HDAC inhibitors on VEGF inhibition in E11 cells. 95% 
confidence intervals are listed within the parentheses. 
 
 HDAC inhibitors 





(3 – 5) 
 
41 
(33 – 52) 
 
78 
(65 – 94) 
 
7 
(27 – 48) 
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B. HDAC Inhibitors Totally Abrogated VEGF-induced HUVEC Angiogenesis 
 Since HDAC inhibitors inhibited VEGF secretion, it was of interest to determine if VEGF-induced angiogenesis was affected. Control 
cells do not form capillary-like structures after the 24 hr incubation. However, VEGF-stimulated cells form distinct capillary-like structures. 
HDAC inhibitors totally abrogated VEGF-induced capillary-like structure formation in HUVECs (Table 7.2).  
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C.  HDAC Inhibitors Suppressed Chemokines in E11 RASF-like Cells in a 
Concentration-Dependent Manner 
 GCP-2, MCP-2 and MIF are three strongly induced chemokines observed in 
RASFs [176, 177]. In order to investigate if HDAC inhibitors affected such 
chemokine secretion, ELISAs were performed. HDAC inhibitors suppressed these 
chemokines in E11 cells in a concentration-dependent manner (Figures 7.2 – 7.4 and 
Tables 7.3 – 7.5).  
 
 In addition, Bay 11-7082 also suppressed GCP-2 and MCP-2 in E11 cells in a 
concentration-dependent manner. At 1, 2.5 and 5 µM, BAY 11-7082 inhibited GCP-2 
by 76.2 ± 2.2%, 82.7 ± 1.7%, 93.6 ± 1.3% (mean ± SD, n= 4); inhibited MCP-2 by 
73.3 ± 2.2%, 85.0 ± 2.0%, 92.4 ± 1.0% (mean ± SD, n= 4), respectively (Figure 7.2 
and Figure 7.3). Clearly, blockade of NF-κB pathway displayed anti-inflammatory 
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Table 7.3 IC50 values of HDAC inhibitors on GCP-2 inhibition in E11 cells. 95% 
confidence intervals are listed within the parentheses. 
 
 HDAC inhibitors 







(5 – 7) 
 
16 























Table 7.4 IC50 values of HDAC inhibitors on MCP-2 inhibition in E11 cells 
 
 HDAC inhibitors 





(28 – 35) 
 
13 
(11 – 16) 
 
1 
(0.9 – 1.6) 












Table 7.5 IC50 values of HDAC inhibitors on MIF inhibition in E11 cells 
 
 HDAC inhibitors 





(1.0 – 2.2) 
 
18 
(14 – 22) 
 
40 
(24 – 47) 
 
1.3 
(1.0 – 1.5) 
  
 





D. HDAC Inhibitors Reduced Monocyte Chemotaxis  
Under control conditions, THP-1 and U937 cells distributed equally into fresh 
medium in the wells. LPS could stimulate E11 cells to secrete various chemotactic 
factors. As a result, about two thirds of THP-1 and U937 cells distributed into 
chemotactic medium. In the presence of HDAC inhibitors, the distribution trend was 
reversed and more than 50% of the cells distributed into fresh medium (Figure 7.5). 
Clearly, HDAC inhibitors reduced E11-driven migration of THP-1 and U937 






































E. HDAC Inhibitors Down-Regulated MMP-2 and MMP-9 Expression in E11 
RASF-like Cells 
MMPs play an important role in cartilage damage and joint destruction in RA 
[2]. Elevated levels of MMP-2 and MMP-9 had been reported in synovial fluids [88]. 
The secretion of MMP-2 and MMP-9 in E11 cells was investigated using substrate gel 
zymography [178]. As shown in Figure 7.6, E11 cells secreted both MMP-2 and 
MMP-9 in pro- forms (pro-MMP-2 and pro-MMP-9) as well as active forms. The 
activity of pro-MMP-2 was observed to be more abundant. LPS stimulation did not 
alter the secretion of MMP-2 or MMP-9 as compared to control cells. However, 
HDAC inhibitors significantly reduced the activities of pro-MMP-2, pro-MMP-9, 
MMP-2 and MMP-9. The pro-MMP-2 and MMP-9 bands became nearly invisible 
after treatment with HDAC inhibitors. Hence, HDAC inhibitors were able to down-
regulate MMP-2 and MMP-9 production in E11 cells.  
 








 Pro MMP-9 
 Pro MMP-2 
           Control LPS      MS-275    SAHA       TSA      PXD1-101 
 MMP-9 
 MMP-2 






VEGF aids angiogenesis in RA by encouraging cell migration and increasing 
vascular permeability [91] to cope with increased oxygen and nutrient demands [91] 
in the diseased tissues. RASFs secrete VEGF and RA patients tend have higher VEGF 
in the synovial fluid [91]. It was observed from clinical studies that the administration 
of anti-TNFα antibodies decreased serum VEGF by up to 40% in RA patients [91]. 
Since HDAC inhibitors could decrease TNF-α here, it was of interest to determine if 
they can reduce VEGF. Indeed, they down-regulated VEGF release from E11 cells. A 
decrease in VEGF secretion is beneficial in RA as this can impede angiogenesis. It 
had been shown from previous studies that HDAC inhibitors suppressed VEGF to 
block angiogenesis in synovial tissues in various arthritis animal models [91]. Indeed, 
it was shown that HDAC inhibitors were able to totally abrogate VEGF-induced 
angiogenesis in HUVECs. 
 
MIF is a pivotal regulator of innate immunity [114, 120]. Its pro-inflammatory 
role in RA pathogenesis had been established [120]. Furthermore, blockade of MIF by 
monoclonal antibody offered in vivo anti-rheumatic efficacy [120]. Hence, MIF 
appears to be a target for RA therapy [120].   Herein, potent suppressive effects on 
MIF were observed with MS-275 and SAHA. To our knowledge, this is the first 
report of the suppressive effects of HDAC inhibitors on MIF in RA synovial 
fibroblasts. As MIF is an activator of p38 [120], inhibition of MIF may further 
attenuate p38 MAPK signaling. Recent evidence indicated that MIF is implicated in 
atherosclerosis [120]. Therefore, the suppression of MIF by HDAC inhibitors may 
offer extra benefits for RA patients, who tend to have a higher incidence of 
atherosclerosis [120]. 





The activation of the innate immune system occurs via specialized pattern 
recognition receptors by conserved bacterial structures such as LPS to mediate host-
pathogen interactions. TLRs are important in recognition of such bacterial 
components [177]. E11 cells could have responded to TLR-2 ligands like LPS by up-
regulating chemokines and MIF. Therefore, chemotactic medium (the supernatant 
derived from E11 cells cultured in the presence of LPS (5 μg/ml) alone attracted 
monocytes. However, HDAC inhibitors significantly reduced monocyte chemotaxis 
by suppressing chemokines like GCP-2, MCP-2 and MIF here. The reduction in 
chemokine secretion and chemotaxis might help to ameliorate inflammation by 
impeding the migration of cells that partake in the process [177].  
 
Bay 11-7082 suppressed tested chemokines (GCP-2, MCP-2 and MIF) 
indicating that NF-κB activation is essential for LPS-induced chemokine production 
in RASFs. Clearly, blockade of the NF-κB pathway displayed anti-inflammatory 
activities since both cytokine and chemokine production were suppressed here. 
Therefore, NF-κB inhibition might be beneficial by reducing chemotaxis. As HDAC 
inhibitors can suppress chemokines as well as or better than Bay 11-7082, it was 
inferred that HDAC inhibitors might be able to suppress chemokine release as a result 
of inhibiting NF-κB activation. In this study, it was demonstrated that HDAC 
inhibitors could suppress chemokine secretion. In turn, monocyte chemotaxis was 
reduced. 
 
MMPs are enzymes that are important for ECM turnover and remodeling 
[178]. There are more than 20 MMPs: collagenases break down fibrillar collagen, 
gelatinases degrade gelatin and basement membrane collagen while stomelysins have 





broader substrate range [177]. MMP dysregulation had been implicated in cancer, OA 
and RA [178]. Collagenase 1, 3, gelatinase A, B and stromelysin 1 are particularly 
important in angiogenesis and RA [178, 179]. Herein, HDAC inhibitors reduced 
gelatinase (MMP-2 and MMP-9) expression compared to the control cells. This may 
translate into decreased ECM degradation which in turn lessens bone and cartilage 
destruction. Angiogenesis may also be impeded as it requires MMPs to occur [178, 
179]. Hence, HDAC inhibitors can be of therapeutic benefit in RA by down-
regulating angiogenesis, chemotaxis and MMP production. 






HDAC inhibitors have emerged as a novel class of anti-cancer agents. Their 
anti-rheumatic activities had been documented in various pre-clinical RA models. 
However, their anti-rheumatic mechanisms of action are not well elucidated. The 
work that was carried out for this thesis aimed to elucidate the anti-inflammatory and 
anti-rheumatic mechanisms of action of HDAC inhibitors. Inhibition of RASF 
proliferation, suppression of pro-inflammatory cytokines, chemokines and NO as well 
as down-regulation of angiogenesis, chemotaxis and MMPs may provide beneficial 
effects in RA. The aforementioned effects may be a result of CDK inhibitor p21 up-
regulation as well as MAPK and NF-κB inhibition. Hence, HDAC inhibitors appear to 
be an innovative strategy for RA management.  
 
It had been noted in our studies that the concentrations of HDAC inhibitors 
needed to exhibit anti-inflammatory and anti-rheumatic activities were lower than 
those required for anti-neoplastic effects. It could be attributed to the fact that the anti-
inflammatory and anti-rheumatic mechanisms of HDAC inhibitors may be different 
from its anti-neoplastic mechanisms. For instance, it had been observed that the IC50 
values for tested HDAC inhibitors to inhibit RASF proliferation were only about 50 
nM while the effective concentration of these HDAC inhibitors in cancer cells were 
usually in the micromolar range [91]. In addition, the effective concentration of 
HDAC inhibitors can be achieved after single oral administration according to phase I 
clinical trials [12, 15, 16, 91]. Hence, it is postulated that the doses of HDAC 
inhibitors used for anti-inflammation may be lower than that required for anti-cancer 
effects. In turn, there may be less dose-dependent side effects. 
 





However, long-term safety is a major concern. More studies may be needed to 
improve the toxicity profiles of HDAC inhibitors. Future investigations could also 
dwell further into other anti-inflammatory and anti-rheumatic mechanisms of action 
of the HDAC inhibitors, focus on characterization of cell-type specific HAT/HDAC-
pattern in RA related tissues, development of HDAC inhibitors with better selectivity 
and establishment of appropriate drug delivery systems for the HDAC inhibitors. 
 
 





8.2 Future Perspectives 
8.2.1 Determine the Relationship between Epigenetics and RA 
The impact of HAT and HDAC activities on RA pathogenesis remains largely 
unknown. Huber et al measured HAT and HDAC activities in the nuclear extracts of 
total synovial tissue samples and found that HAT activities remained unchanged in 
osteoarthritis (OA), RA and arthritis-free controls while HDAC activities were 
suppressed in OA and RA compared to controls [138]. It was then deduced that 
HDAC down-regulation contributed to OA and RA hence HDAC up-regulation offers 
therapeutic strategies [138, 180].  
 
Recently, it had been discovered that the transcription of MMP-10 could be 
induced in mammary epithelial cells by transforming growth factor (TGF)-β, through 
the activation of monocyte enhancer factor (MEF)-2A and down-regulation of class 
IIa HDACs [181]. In general, TGF-β helps to regulate MMPs and ECM components 
[181]. TGF-β was found to up-regulate the MMP-10 promoter through the MEF-2A 
site as MEF-2A knockdown negatively affected MMP-10 induction [181]. In the 
presence of TGF-β, acetylaton and binding of MEF-2A to the MMP-10 promoter 
region was increased [181]. Class IIa HDACs could interact with MEF-2 to suppress 
the transcription and expression of MMP-10 by reducing the level of acetylation [181]. 
However, TGF-β promoted proteasome-dependent degradation of HDACs [181]. 
Hence, acetylation of histones was increased around the MEF-2A site of the MMP-10 
promoter [181]. Therefore, it was concluded that TGF-β up-regulated the transcription 
of MMP-10 through MEF-2A activation and increased acetylation of histones around 
the promoter, as a result of the degradation of class IIa HDACs [181]. In a similar 
perspective to the study by Huber et al [138], it implied that HDAC down-regulation 





contributed to MMP induction while HDAC up-regulation offers therapeutic 
strategies [180].  
 
However, it appears insufficient to conclude that reduced HDAC activities are 
indeed associated with OA or RA as there was a limited sample (RA: 7, OA: 6 and 
arthritis-free controls: 5) [138]. Results should be confirmed in a larger population. 
Furthermore, it is rather inconceivable that HDAC contributed to both OA and RA 
pathogenesis. Although OA and RA etiologies remained unclear, disparities exist 
between OA and RA. OA is a degenerative disease with chondrocyte senescence 
while RA is an auto-immune disease with highly proliferative synovium. It is difficult 
to establish that decreased HDAC activities can mediate the pathogenesis of two 
apparently distinct diseases. Besides synovial inflammation, multiple cells including 
B cells, T cells, macrophages, monocytes, chondrocytes and osteoclasts are also 
involved in RA [2]. The activities of HAT and HDAC within such cells have not been 
assessed in the RA patients. As it is generally believed that RA is initiated by antigen-
dependent activation of CD4
+ 
T cells [2], the abnormalities of HDAC activities in 
synovial tissues could be resultant of RA and not cause. Finally, if reduced HDAC 
activities contributed to RA pathogenesis, further HDAC down-regulation by HDAC 
inhibitors would worsen RA. However, the anti-rheumatic efficacy of HDAC 
inhibitors in various pre-clinical models had been reported by at least five 
independent research groups [29-33]. Therefore, reduced HDAC activities in RA 
could be an epiphenomenon due to chronic inflammation [33]. Further investigations 
will be required to determine the relationship between decreased HDAC activities and 
RA pathogenesis.  





8.2.2 Another Mechanism of Action: HDAC Inhibitors may Exhibit 
Immunomodulatory Effects via Forkhead Box P3 (FOXP3
+
) Tregs 
In order to maintain immunological unresponsiveness to self-antigens, it is 
necessary to inactivate and eliminate potentially harmful self-reactive lymphocytes as 
they are being generated [18]. This process occurs in the thymus [182]. For the 
lymphocytes which manage to escape inactivation or elimination in the thymus, there 
is a second line of defense. They can be suppressed in the periphery by CD4
+
Tregs 
[183]. Natural Tregs occur during thymic development before they enter the periphery 
[183]. Since Tregs engage in the maintenance of immunological self-tolerance by 
actively suppressing self-reactive lymphocytes, it plays a substantial role in 
autoimmunity [183]. FOXP3 has been identified to be the key for the development of 
Tregs [183]. They were found to modulate the expression of hundreds of genes when 
transfected into T cells. In recent years, FOXP3
+
Tregs had been identified to maintain 
immune homeostasis [184], as illustrated by fatalities found in patients with immuno-
dysregulation, plyendocrinopathy and enteropathy [185-191]. This cell type has 
therefore emerged as a therapeutic target in autoimmunity and transplant rejection 
[191].  
 
The acetylation of FOXP3 was observed to enhance the binding of human 
[189] and murine [190] FOXP3 to the chromatin as well as their effects on gene 
expression in Tregs. Co-IP analyses found a physical association between FOXP3 with 
deacetylases like HDAC7 and 9 [189]. The studies suggested that FOXP3-dependent 
Treg functions could be modulated by acetylation. Increasing FOXP3 acetylation was 
identified to be a potential strategy to reduce autoimmunity. The aforementioned was 
observed to be achievable via HDAC inhibitor therapy [189-191].  





At nanomolar concentrations, hydroxamic acid-based pan HDAC inhibitors 
like M344, SAHA, Scriptaid and TSA suppressed Tregs in vitro [192]. They increased 
FOXP3 mRNA expression and enhanced peripheral conversion upon adoptive transfer 
of T cells into immunodeficient mice [190]. In addition, pan HDAC inhibitors 
reduced inflammatory responses in arthritis [193]. At micro and millimolar 
concentrations, short chain fatty acid-based HDAC inhibitors like PB and VPA also 
promoted Treg function [193]. However, quinolone-based HDAC inhibitor like 
NSC3852 as well as benzamide-based inhibitors like MS-275 and MS-1293 did not 
affect FOXP3 or FOXP3
+
Treg function [193]. The same differences between pan 
HDAC inhibitors (SAHA, TSA) and class I specific HDAC inhibitors (MS-275) were 
demonstrated in a mouse colitis model [194]. Although class I specific HDAC 
inhibitors fail to influence Treg function, these agents still possess important dose-
dependent anti-inflammatory effects in vitro and in vivo [59, 85]. In CIA, MS-275 
was more efficacious than SAHA in preventing joint destruction [22, 59] while TSA 
was highly effective in AIA [19]. The reasons for such disparities observed are still 
unknown but they might stem from differences in drug potencies and sets of genes 
induced [42]. Since pan HDAC inhibitors but not class I specific HDAC inhibitors 
enhanced Treg function, it can be postulated that class II HDACs play a role in 
regulating T cells. Biochemical data revealed that HDAC7 and 9 associated with 
FOXP3 in large supra-molecular complexes but these class IIa HDACs tend to have 
weak deacetylase activities. Hence, targeting class IIb HDACs might be more 
advantageous [184]. 
 
Class IIa selective HDAC inhibitors are not widely available therefore there 
had been very little data on their efficacy in vivo [195-199]. To date, there is only 





genetic evidence to demonstrate the value of class IIa selective inhibitors in regulating 
Treg function. FOXP3
+
Tregs isolated from HDAC9-deficient mice showed increased 
suppressive functions in vitro and in vivo [190, 194]. Such Tregs also possessed greater 
HSP70 levels and are resistant to apoptosis [194]. Preliminary data also showed that 
HDAC7 inhibition increased Treg function in vitro and in vivo [184]. HDAC7 was 
found to function as a brake on normal FOXP3-dependent Treg function as HDAC7 
deficient mice enhanced the suppressive function of Tregs yet did not affect CD4, CD8 
or Treg numbers [184]. Class IIb HDAC (HDAC 6) selective inhibitor such as tubacin 
also increased the suppressive function of Tregs in vitro by increasing the expression of 
CTCLA4, IL-10, programmed cell death protein-1, FOXP3
+ 
Tregs and other Treg related 









 Tregs and decreased cytokine production, except that of IL-10 and IL-17 
[200]. These effects were shown to be comparable to geldamycin which is a HSP90 
inhibitor [200]. Hence, the effects of tubacin were thought to be partly mediated by 
HSP90 inhibition [200]. Tubacin was shown to decrease disease severity in murine 
dextran sodium sulphate and CD4
+
CD26L adoptive transfer colitis models [201]. 
Therefore, HDAC inhibitors that can block class IIa HDACs (HDAC7 and 9), class 
IIb HDACs (HDAC6) or promote HSP70 expression in Tregs could be valuable in 
regulating immune responses in autoimmune diseases like RA. 
 
However, care has to be taken when extrapolating T cell biology from animals 
to human as discrepancies exist. For instance, IL-35 is basally expressed in murine 
FOXP3
+ 
Tregs and can promote the suppressive function of Tregs but they are not 
expressed in humans [202]. Besides, the conversion of murine T cells to Tregs occurs 
upon activation by IL-2 and TGF-β but this does not occur in humans reliably [203]. 





In addition, the suppressive function of Tregs was not always observed to be beneficial. 
In cancer, the recruitment of Tregs counteracts host anti-tumor immune responses [204], 
leading to increased resistance. This had been observed clinically [204] as well as in 
murine models of type 1 diabetes [205]. Although HDAC inhibitors have the potential 
ability to modulate immunity by therapeutically targeting FOXP3
+
 Tregs, effector T 
cells, dendritic cells and other cellular components of the inflammatory cascade, their 























8.2.3 Characterization of a Cell-Type Specific HAT/HDAC-Pattern in RA 
Related Tissues 
 Aberrant epigenetics can contribute to the pathogenesis of various diseases 
[206]. However, the impact of epigenetic regulation on RA development has not been 
well studied although reduced HDAC activities had been observed in both OA and 
RA synovial tissues in a pilot study [60]. HDAC inhibitors were shown to decrease 
cell viability and induce cell cycle arrest as well as apoptosis in RASFs [50, 59] but 
the HDAC inhibitors used were not specific for any particular HDAC hence it was 
difficult to determine the functional significance of each HDAC. In cancer cells, 
HDAC2 tend to be over-expressed in colorectal, cervical and gastric cancers [206, 
207]. A knockdown of HDAC1 and HDAC2 was shown to inhibit cell growth and 
induced p21 and p53 proteins in tumor cells [206]. Subsequently, Hirouchi et al 
discovered that RASFs expressed higher mRNA levels of HDAC1 than OASFs. They 
concluded that HDAC1 over-expression in RASFs might be involved in their tumor-
like characteristics [206]. A knockdown of HDAC1 and HDAC2 then resulted in 
RASF apoptosis [206]. HDAC1 knockdown also down-regulated MMP-1 production 
[206]. Taken together, HDAC1 over-expression was characteristic of RASFs and its 
knockdown might aid in the inhibition of cell proliferation and MMP-1 production.  
 
Beside HDAC1 and HDAC2, it would be intriguing to determine the functions 
of other HDACs. Moreover, apart from RASFs, B cells, T cells, macrophages, 
monocytes, chondrocytes and osteoclasts are also involved in RA pathogenesis. RA 
often involves synovial hyperplasia and the panus forms in late disease. Therefore, 
assessment of epigenetic statuses, e.g. HATs and HDACs in immune cells like B cells, 
T cells as well as macrophages in RA patients can be relevant to determine whether 





epigenetic abnormalities contribute to RA development. Future work can focus on the 





























8.2.4 Toxicity Profiling of HDAC Inhibitors 
The toxicities of HDAC inhibitors were reported when they increasingly 
entered clinical trials [208, 209]. Neurological effects like ataxia, confusion or 
somnolence were observed with butyrate, MS-275 and PB but not with AN-9 and CI-
994 [208]. VPA had been used for decades as an anti-convulsant and mood-stabilizer 
[209, 210]. Unfortunately, therapeutic drug monitoring is required because of its low 
therapeutic index [27]. Central nervous system side effects, nausea and vomiting as 
well as thrombocytopenia might occur at high doses [210, 212]. With SAHA, 
anorexia, dehydration, diarrhea, fatigue [213] and non-specific electrocardiogram 
changes without clinical signs or symptoms [214] were reported.  
 
The side effects of HDAC inhibitors were generally considered to be tolerable. 
However, serious adverse events like atrial fibrillation, tachycardia and ventricular 
arrhythmia had been observed with FK-228 [215, 216]. These toxicities might not 
necessarily be of major concern while using HDAC inhibitors for cancer as benefits 
may outweigh the risks of treatment. However, if HDAC inhibitors were used in RA, 
side effects are of important consideration, attributed to the fact that RA is life-long 
and requires chronic treatment or at least treatments of intermediate durations as the 
disease flares and wanes. To date, long-term clinical safety of HDAC inhibitors has 
not been well established. The adverse effects of HDAC inhibitors reported in 
oncology can be expected to occur in RA patients.  
 
Fortunately, the concentration of HDAC inhibitors required to exhibit anti-
inflammatory activities may be lower than for anti-neoplastic effects as the 
mechanisms of action of HDAC inhibitors in the two situations may differ. It was 





noticed that IC50 values for HDAC inhibitors to inhibit RASF proliferation were only 
about 50 nM while the effective concentration of  HDAC inhibitors in cancer cells 
were usually at micromolar levels [207, 208]. Moreover, at sub-micromolar levels, 
SAHA exhibited in vitro anti-inflammatory activities by suppressing IL-1β, IFN-γ and 
TNF-α in human peripheral blood mononuclear cells and NO in murine peritoneal 
macrophages [17]. It could therefore be postulated that the dose of SAHA needed for 
anti-inflammation may be lower than for anti-neoplasm. Whereas in other studies, the 
levels of FK-228, PB and TSA that inhibited RASF growth (IC50: FK-228, 10 - 100 
nM; PB, 2 mM; TSA, 100 nM) were within or higher than levels to cause cancer cell 
growth arrest [11, 217, 218]. Interestingly, HDAC inhibitors also inhibited the 
proliferation of both normal and transformed synovial tissues without inducing 
apoptosis or necrosis [19, 20]. Growth arrest was reversible in normal synovial tissues 
but not in RASFs when the HDAC inhibitors were removed [19]. Therefore, 
continuous presence of HDAC inhibitors was probably not crucial, allowing for 
intermittent therapy. It is also relatively difficult to compare the effective 
concentrations required for anti-cancer and anti-inflammation from the results of 
previous studies because of different cells or models used for the two purposes. Hence, 
it may be more practical to compare the in vivo effective doses for these two effects. 
For FK-228, MS-275 and SAHA, the effective anti-rheumatic doses were within the 
range of anti-cancer doses used in previous studies (FK-228: 0.32-4.4 mg/kg [11]; 










8.2.5 Developing New Generations of HDAC Inhibitors 
It is known that drug molecules with high specificity to target receptors or 
enzymes usually lead to less side effects as they may have less interferences with 
other physiological pathways. Therefore, selective HDAC inhibitors can be developed. 
However, many HDAC inhibitors with excellent clinical prospects, including 
LBH589, PXD-101, SAHA and VPA (Table 1.2) are pan inhibitors for Class I and II 
HDACs. Although anti-inflammatory activities of HDAC inhibitors had been reported 
in various pre-clinical models, HDAC isoform(s) involved in inflammatory or anti-
inflammatory processes have yet to be identified. It is crucial to find out whether 
abnormality of an individual HDAC triggers or contributes to RA pathogenesis. 
Furthermore, RA may not be driven by HAT or HDAC, although HDAC inhibitors 
could exhibit their anti-inflammatory activities through up-regulation of some anti-
inflammatory genes, suppression of some pro-inflammatory genes and possibly both.  
 
With recent progresses in biotechnology, identification of individual HDAC 
involvement in RA pathogenesis and individual HDAC contribution to anti-
inflammation may be possible. Silencing specific HDACs with RNA interference in 
RA related cells like synovial fibroblasts, B cells, T cells, macrophages and 
monocytes may determine whether HDAC contributes to RA development. Similarly, 
DNA microarray studies can identify changes in gene expression caused by HDAC 
inhibitors, in order to locate HDAC inhibitor target genes. With information obtained 
from these technologies, HDAC isoform(s) relevant to RA pathogenesis or therapy 
can be elucidated.  
 





Advances in medicinal chemistry also allowed significant breakthroughs in the 
development of isoform-specific HDAC inhibitors. Investigations may be carried out 
on the HDAC enzyme itself, with the intent of structure based drug design (SBDD) 
[219]. For instance, the study of 14A internal cavity adjacent to the enzyme catalytic 
site led to the discovery of a unique bis(aryl)-type pharmacophore. Using structural 
activity relationships (SAR), this lead was further optimized to produce hydroxamic 
acids that target HDAC 1 and 2 only [220]. And the exploration of nicotinamide core 
within benzamide HDAC inhibitors led to class I selective HDAC inhibitors which 
demonstrated in vivo efficacy in a HCT116 xenograft model [209]. In addition, 
targeted compound libraries could be screened. In the case of apicidin, a screen 
dedicated to the search of L-2-amino-8-oxodecanoic acid (L-Aoda) derivatives 
identified a small acyclic molecule with an unusual ketone zinc binding group. SAR 
around this lead resulted in selective HDAC inhibitors acting on HDAC 1 in various 
cell lines [221]. Hence, if inflammation was mediated by a specific HDAC or 
inhibition of a certain HDAC exhibited anti-inflammatory activities, isoform specific 
HDAC inhibitors can be appropriate strategies.  
 
Class I HDAC-specific HDAC inhibitors like FK-228 and MS-275 appeared 
to be more potent than pan HDAC inhibitors like PB and SAHA [20, 22]. However, 
there is still insufficient evidence to conclude that Class I HDACs are therefore 
implicated to greater extent in inflammation than the Class II counterparts.  
 
Drawing from the Abbott experience, several elements are required in 
development of selective HDAC inhibitors. SBDD and targeted screens were 
employed, albeit a serendipitous discovery of biaryl hydroxamate A-161906. 





Subsequently, selectivity was assessed using siRNA gene knockdown studies. 
Eventually, the lead proved too toxic in anti-proliferation studies. Hence, SAR was 
utilized to replace the hydroxamate by an alpha-ketoamide that produced good 
cellular activities [222]. Based on a better understanding of the mechanisms of action, 
new generations of HDAC inhibitors with better specificity and safety profiles can be 
established. As mentioned earlier, this could be achieved by SBDD, targeted screens 
of dedicated libraries, SAR, siRNA and gene chip studies with engineered cell lines 
relevant to RA like E11 [223] as well as selecting appropriate RA directed animal 
models, broadly divide into three types based on the immunogen used to induce 
murine arthritis; namely AIA, cell wall derivative and CIA models [23]. But, it should 
be noted that although all these animal models share similarities with human RA, they 
do not completely mimic the condition [23]. Therefore, the in vivo efficacy of lead 


















8.2.6 Developing Appropriate Drug Delivery Systems for HDAC Inhibitors 
Drug delivery systems and formulation optimization should also be considered. 
The major concern of HDAC inhibitors in RA therapy is its long-term safety. Local 
administration of HDAC inhibitors to affected joints could bypass the toxicity issue 
hence topical application may be a practical strategy. PB cream and TSA ointment 
have demonstrated in vivo anti-rheumatic efficacies in a rat AIA model, with effects 
longer lasting than oral HYD [42]. However, topical formulations may be 
inconvenient to administer. Hydrogel containing HDAC inhibitors may be injected 
directly into the rheumatic joints. These sustained-release formulations may help 
control local inflammation in one or more joints over a prolonged period of time, 
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